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ABSTRACT 
 
The isolation of beta-islets from the pancreas and their 
microencapsulation in a polymeric matrix render them susceptible to hypoxic and 
hypoxia-induced free radical stresses, causing enhanced apoptosis in vitro and 
at the site of transplantation. This research project focused on low p50 
hemoglobin (Hb) conjugates with the antioxidant enzymes, superoxide dismutase 
(SOD) and catalase (CAT), for Hb’s protection from free radicals and from the 
combined oxidative and hypoxic stress for beta-islets. This dissertation is an 
account of the enhanced cell viability of beta-cells for an advancement toward a 
biohybrid artificial pancreas.   
A poly(ethylene glycol) cross-linker used in an optimized Hb:PEG molar 
ratio (1:10) dramatically reduced methemoglobin formation. The addition of 
antioxidant enzymes with hemoglobin (Hb-SOD-CAT) inhibited methemoglobin 
formation during storage at 4 °C for a month and also when subjected to external 
oxidative stress. The size of conjugates obtained by cross-linking was also 
optimal for coencapsulation with beta-cells, thus preventing the diffusional loss of 
Hb conjugates from the microcapsules.  
The addition of poly(ethylene glycol) cross-linked Hb-SOD-CAT 
conjugates with low p50 characteristics and antioxidant properties showed 
enhanced protective effects on pancreatic cells (RINm5F cells) when incubated 
iv 
 
in hypoxic (1% oxygen) conditions, as higher oxygen amounts are released in 
hypoxic condition. Combined hypoxic and free radical (hypoxia-induced) stress 
conditions are encountered during islet transplantation. RINm5F cells that had 
been incubated in hypoxia and challenged with oxidants (hydrogen peroxide and 
superoxide anion) showed low intracellular free radical activity on addition when 
optimized Hb-SOD-CAT conjugates was added. These optimized Hb-SOD-CAT 
conjugates also help maintain glucose-induced insulin secretion from pancreatic 
beta-islets in combined oxidative and hypoxic stress experiments.  
In summary, the potential of Hb-SOD-CAT conjugates to reduce the 
dysfunction of beta-islets associated with free radical and hypoxic stress has 
been demonstrated. It is likely that antioxidant enzymes will play a significant role 
in the protection of hemoglobin in these conjugates and consequently will 
enhance cell viability. Consequently, the use of Hb-SOD-CAT conjugates in a 
biohybrid artificial pancreas consisting of an oxygen carrier, antioxidants, and 
pancreatic beta-islets in microcapsules has the potential to provide a better 
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1.1  Physiology of the pancreas 
1.1.1  Pancreas 
The human pancreas contains approximately one million beta islets in the 
islets of Langerhans, the regions of the pancreas containing endocrine cells that 
distribute insulin throughout the exocrine tissues. Comprising 1% to 2% of the 
total mass of the pancreas, the islet of Langerhans contain four different cells 
types: beta cells, which produce insulin and decrease blood glucose levels; alpha 
cells, which produce glucagon and raise blood glucose levels; delta cells, which 
secrete somatostatin to inhibit the endocrine activity of the pancreas; and 




1.1.2  Insulin secretion and regulation 
Although insulin is only produced by beta cells, insulin receptors are 
widely distributed on most types of cells (2). When the blood glucose level is 
elevated after digestion, insulin is released from the beta cells to convert glucose 
to glycogen via glycogenesis, which returns the elevated blood glucose level to a 
normal level. In the event of a drop in the normal blood glucose level, glucagon 
will be released by alpha cells to increase the blood glucose level by converting 
glycogen into glucose via glycogenolysis, a process mediated by the liver (3). 
Beta cells secrete insulin in response to exogenous glucose stimulation. On 
sensing elevated glucose, beta cells begin insulin synthesis by activation of two 




Glut2 receptor, which is phosphorylated by Glucokinase. Glut2 expression 
changes on the beta cell and responds to insulin synthesis based on whether the 
physiological state is diabetic or hyperglycemic. Insulin mRNA is translated into 
proinsulin, which contains the A and B chains of insulin linked by a C-peptide, a 
structure that helps align the disulfide bridges. Proinsulin is further processed in 
the maturing granule to insulin with the removal of the C-peptide by the 
endopeptidases. The insulin molecule binds coordinately with zinc (Zn) to form 
hexamers (2, 5). The synthesized insulin is transported in the blood, where it 
decreases elevated blood glucose levels by transporting glucose into the cells.  
The insulin receptor on the cells belongs to the tyrosine kinase receptor 
family. When insulin binds to the insulin receptor, the substrate protein insulin 
receptor substrate 1 (IRS-1) is phosphorylated by tyrosine kinase. This leads to 
an increase in the number of glucose transporter (Glut4) molecules on the outer 
membrane of glucose-responsive cells, resulting in increased uptake of glucose 
from blood into the tissues. This glucose is further converted into glycogen and 
fatty acids or metabolized to produce energy (5). 
 
 
1.2  Diabetes  
Diabetes mellitus or diabetes is a metabolic disorder state in which blood 
sugar levels are elevated either because the body does not produce sufficient 
insulin or because the insulin produced is not utilized effectively by body cells. 
Diabetes is categorized into Type 1 diabetes (6), also known as insulin-




body fails to produce sufficient insulin and Type 2 diabetes (7), a condition in 
which insulin resistance and/or beta-cell failure results in insufficient insulin 
production. 
 
1.2.1 Epidemiology of diabetes  
The American Diabetes Association (ADA) estimates that nearly 24 million 
children and adults or 7.8% of the total population currently suffer from diabetes 
in the United States, of whom approximately 12 million are men and 11.5 million 
are women. According to death certificate data, diabetes is the seventh leading 
cause of death in the United States, in which an ADA estimated 1.6 million new 
cases are diagnosed every year. Of the 24 million Americans who suffer from 
diabetes, 5% to 10% suffer from Type 1 diabetes, a complex disease requiring 
lifelong insulin therapy. It has been estimated that approximately US$174 billion 
were spent on diabetic patients in 2007 (8). The World Health Organization 
(WHO) estimates that 285 million (6.4%) of the world population of 7 billion lives 
with diabetes, of whom 50.8 and 43.2 million live in India and China, respectively 
(9), and of whom approximately 480,000 are children suffering from Type 1 
diabetes, the more common form among young children (10). WHO estimates 
that if the financial burden of diabetes is expressed in International Dollars (ID) 
that take into account differences in purchasing power, the global financial 
burden of diabetes was 418 ID billion in 2010, and projects it to increase to 561 




  Apart from the enormous financial burden that diabetes imposes, current 
treatment of the disease requires the administration of multiple daily insulin 
injections, which is associated with poor patient compliance. Type 1 diabetes is 
also associated with long-term complications, such as diabetic retinopathy, 
cardiovascular disease, nephropathy, neuropathy, and atherosclerosis. The 
current ADA recommendation is to maintain glycosylated Hb (HbA1c) levels 
below 7% to control the disease and its associated complications (8). 
 
1.2.2 Pathophysiology of Type 1 diabetes  
Type 1 diabetes is an autoimmune disorder characterized by the complete 
absence of insulin production resulting from attacks on the beta cells in the islets 
of Langerhans by the body’s immune system, which renders the beta cells 
incapable of insulin production (6). In most Type 1 diabetics, more than 90% of 
their islets have been destroyed by T-cells (11-13). This disease may be caused 
by genetic factors; environmental factors (14), such as viruses (15); vitamin 
deficiencies (16); chemically induced oxidative stress (streptozotocin) (17); 
and/or other unknown factors. The pathogenesis of beta-cell apoptosis involves 
the development of spontaneous auto-antigens and associated cellular 
(macrophage, dendritic cell, B lymphocyte, and T-cell) involvement (18). The 
main mechanism of beta-cell apoptosis in Type 1 diabetes is cytokine-mediated 
apoptosis, as opposed to high-glucose associated toxicity, which is the main 
mechanism in Type 2 diabetes (19). Other mechanisms, if any, are not very well 




obtained from exogenous sources and careful monitoring of blood glucose levels 
throughout the life of the patient. 
 
 
1.3 Type 1 diabetes treatments and associated problems 
Several approaches are currently being investigated to treat 
hyperglycemia and related complications of Type 1 diabetes (Table 1.1). The 
major limitation of the most commonly used approach, the administration of 
exogenous insulin, is patient inconvenience in monitoring and maintaining proper 
glucose levels (20). Although the use of insulin pumps is an attractive alternative, 
it requires improvement, and still requires the self-monitoring of blood glucose to 
maintain metabolic control. Although they have been improved, sensors and 
continuous glucose monitors are still inconvenient to use (21, 22). 
An ideal solution is to replace the nonfunctioning endocrine part of the 
pancreas with healthy tissue that can produce insulin. However, doing so 
requires substitution of the entire pancreas with a healthy pancreas from a 
suitable donor. Such transplantation is infeasible for several reasons, including 
immune rejection of the transplanted organ, the limited off-shelf availability of a 
suitable pancreatic organ donor, and complications associated with the surgical 
procedure (23). At present, transplantation is limited to patients with severe 
insulin-dependent diabetes and associated complications, and is usually 
associated with simultaneous kidney transplant from the same donor, as 
pancreas-only transplantation tends to result in serious side effects on kidney 




Table 1.1: Current treatment options for Type 1 diabetes 





























Islet scarcity & 
Immune 
suppression 
Difficult to manage 
glucose fluctuations 
 
Weight gain Immune 
suppression; 
kidney damage  
Duration of cell 
survival 
 
thrombosis, infection, pancreatitis, and serious immune rejection, apart from 
donor scarcity and the need for a complex surgical procedure (23).  
An alternative practical solution to entire organ transplantation is 
transplantation of isolated islets or islets from different sources (autogenic, 
allogenic, xenogenic, and/or artificial cell lines), which requires minimal and less 
invasive surgery. One of the many problems with transplanted islets from 
nonhuman sources/donors, that of rejection by the immune system, can be 
avoided by using either immunosuppressive drugs such as sirolimus (24), a 
cellular antiproliferative agent  or an antibody-mediated immune modulating 





1.3.1 Clinical trial: Islet transplantation with immunosuppressive  
regimen 
A research group in Edmonton, Alberta that achieved normal insulin 
production and normoglycemia in many patients via islet transplantation 
according to the Edmonton protocol (27) has conducted the most successful 
clinical trial of islet transplantation. In this trial, the team transplanted 9,000 
allogenic islets/kg into the liver of each patient, a procedure that required 2 to 4 
healthy human pancreas to treat a single patient (28), and that was found to have 
restored normoglycemia of greater than 50% one year after transplantation. 
However, the need for 2 to 3 donors per islet transplant makes this approach 
infeasible, and the need for immunosuppression throughout the lifetime may 
make it unsuitable for maintaining long-term normoglycemia (27-31).  
 
1.3.2 Islet scarcity 
To some extent, the problem of islet scarcity can be resolved using new 
approaches, including islet regeneration therapy (32, 33), in which beta cells 
arise primarily from preexisting beta cells, and the generation of islets from stem 
cells (34, 35). In the genetic engineering approach, the insulin-producing gene is 
inserted into non-insulin-producing cells or into cells that are sensitive to glucose 
(36). However, the genetic engineering approach faces several limitations. Even 
though islet scarcity can be resolved to some extent using the above 
approaches, islet transplantation requires immunosuppression throughout the 




very difficult for patients unless they are combined with other technologies that 
circumvent the need for immunosuppression. A feasible alternative approach that 
reduces immune rejection is to transplant only the insulin-producing beta cells. 
One such approach that is currently being pursued is the bioartifical pancreas 
(BAP) approach, which uses isolated islets (37-39) and biocompatible polymers 
to prevent the entry of modulators of immune response. Although islet 
transplantation has been demonstrated to have some success in clinical settings, 
it requires improvement to reduce the incidence of hypoxia and free-radical-
induced islet death. Prevention of hypoxia-induced-islet apoptosis is a key factor 
in maintaining long-term insulin secretion and successful islet transplantation.  
 
1.3.3 Islet transplantation without immunosuppression: The BAP 
A bioengineering approach that has significant advantages over the above 
approaches, BAP employs islet encapsulation with islet-protecting biological 
molecules, such as oxygen (O2) carriers, and signaling molecules, such as 
glucagon-like peptide 1, using a physical barrier. This semipermeable 
biocompatible physical layer allows the diffusion of secreted insulin across the 
physical barrier and assists in the mass transport of other essential nutrients by 
diffusion and the removal of waste materials from the bioartificial pancreas. The 
material barrier around the islets prevents the triggering of the immune response 
by inhibiting attack by immune cells and by preventing a foreign body response, 
and could thus potentially prevent graft rejection. This approach may also 




surgery, as the implant can be transplanted in the liver through the portal system 
or in the peritoneal cavity (37-39). Although many researchers have 
demonstrated successful islet transplantation without immunosuppression, a 
significant number of hurdles are yet to be overcome. One such problem is the 
extremely large size of the implant, as a large number of microencapsulated 
islets (15,000-20,000 islets/kg of body weight) are required to achieve 
normoglycemia (40). 
 
1.3.4 Immunoisolation devices 
Based on their geometry and configuration, BAP devices are generally 
divided into the two main categories of 1) macrodevices/capsules and 2) 
microcapsules. Although both categories are being evaluated, microcapsules are 
currently more popular, as they are easy to retrieve and help keep the endocrine 
tissue together. However, these devices have the drawbacks of tissue loading, 
large size, potential for fibroblast growth inside the tissue, and lack of scalability 
to humans (23, 41). A vascular prosthesis in which islets are seeded within a 
special immunoselective chamber has shown some success in a dog model (42, 
43), and is currently popular. However, its success in humans may be limited 
because of the risk of thrombosis and vascular accidents if the device fails.  
In BAP systems using microcapsules, the materials used for the physical 
barriers are primarily polymers, such as alginate, poly-L-lysine, and poly-L-
ornithine. The most currently successful approach is achieved by 




microcapsules, which can be transplanted both extravascularly and 
intravascularly (41), have better diffusion capacity compared to macrocapsules, 
are easy to transplant, and require minimal surgery. The encapsulation of 
individual islets inhibits fibroblast growth (44, 45), but the islets are difficult to 
retrieve. It has been shown that the ideal capsules range was around 700 µm in 
size and has no imperfections in their shape (46). Polycations such as poly-L-
lysine bind to the alginate molecules and induce ionic complex formation at the 
capsule surface, which decreases the porosity of the membrane. The molecular 
cutoff diameter of the immunoisolation device can be controlled with the content 
of poly-L-lysine (47).  
Current methodologies, including electrostatic droplet generation (48), 
gradient centrifugation (49), and photopolymerization (50), can decrease the size 
of microcapsules and the implant volume. However, the fundamental problems 
associated with islet viability, apoptosis, and necrosis inside the capsules by 
hypoxia and free-radical damage must be addressed when immunoisolation 
techniques are used.  
 
1.4 Cell death 
 
Cell death within the body occurs by different intracellular and extracellular 
pathways ways and is mediated by different mechanisms. Programmed cell 
death can be apoptotic (Type 1) or autophagic (Type 2). In apoptotic cell death, 
which is characterized by mitochondrial dysfunction followed by activation of 




shrinkage, nuclear disintegration, and DNA fragmentation (51). Autophagic cell 
death due to the recycling of cytoplasm and the elimination of defective 
organelles, processes that regulate cellular homeostasis, is characterized by the 
appearance of double-membrane-containing vacuoles in the cytoplasm and the 
fusion of autophagosomes with lysosomes (52). Regulatory proteins, such as 
caspases and proteins of the bcl-2 family are primarily involved in cell death, and 
the activation of death receptors, such as the TNF receptor-1 and the Fas 
receptor, on the cell surface will cause cell death (52). Cell death can also occur 
by other apoptotic-mediated means due to cell stress or trauma, whether 
caspase-independent or necrotic in nature. 
 
1.4.1 Cell adaptations and death under hypoxia 
During hypoxic conditions, cells react to a demand for O2 that exceeds 
availability by changing their metabolism, such as by increasing respiration via 
new blood vessel recruitment and erythropoiesis, the production of new red blood 
cells (RBCs). However, if chronic hypoxic conditions persist, cells change their 
means of respiration from aerobic to anaerobic, which reduces cell energy usage 
and decreases cell proliferation to meet the O2 availability. Under normoxia, cells 
convert glucose into pyruvate, which is catalyzed in a respiratory reaction to 
produce ATP. However, under hypoxia, pyruvate is converted into lactate due to 
the shift in metabolism to an anaerobic pathway. Specifically, acidification of the 
microenvironment due to lactic acid production and reduced dispersion or 




in cellular metabolism. To some extent, cells adapt to this situation by up-
regulation of carbonic anhydrase enzyme, which converts CO2 to carbonic acid 
and allows cells to adapt to the acidic microenvironment (53). 
Hypoxia causes autophagy through different mechanisms and depends on 
hypoxia-inducible factor (HIF). Researchers have found that if O2 levels fall 
below 5%, the alpha subunit of the protein stabilizes, combines with the beta unit, 
and is expressed and elevated (54). Researchers have also found that additional 
pathways activated under severe hypoxic conditions can cause autophagy (55). 
Additional proteins, such as DJ-1, can also cause cell death by an unknown 
mechanism, as can PDGFR-dependent autocrine stimulation, stress-mediated 
metabolic stimulation, and up-regulation of endoplasmic reticulum (55, 56). In 
research examining isolated cell cultures, hypoxia has been found to cause 
significant changes at the metabolic level by activation or inhibition of the various 
enzymes and transporters discussed above, with the duration, severity, and type 
of cells studied determining the type of pathways activated or inhibited, which 
cannot be consistently defined (57). 
 
1.4.2 Cell adaptations and death in a free-radical environment 
Under conditions of normal O2 levels, electron flow (1 to 2%) throughout 
the mitochondrial respiratory chain leads to the production of reactive oxygen 
species (ROS), which serve as signaling molecules in regulating cellular activity 
by controlling the oxidized targets (58), and are thus essential in cellular 




in hypoxic conditions due to lower levels of O2, the ROS level has been found to 
increase in such conditions (57). Specifically, it has been demonstrated that 
hypoxia triggers mitochondrial ROS, which have a significant role in HIF-1α 
stabilization during hypoxia (57). It has also been found that the sensing of low 
O2 levels and the stabilization of free-radical-mediated HIF-1aplha are mediated 
by the mitochondrial respiratory chain (57). ROS are known to be produced 
during cellular hypoxia within different cells types, such as pulmonary artery 
smooth muscle cells and cardiomyocytes that produce increased ROS, which are 




1.5 Islet hypoxia and possible approaches to its prevention 
 
Islets are prone to hypoxic conditions during the stages of isolation (60), 
culturing (60), encapsulation (61), and transplantation (62). Most islets are 
susceptible to hypoxic conditions because of the enzymatic separation of islets, 
and thus the loss of blood vasculature or the network of blood capillaries around 
islets. Islets depend on surrounding blood vessels for their blood supply in vivo 
and after isolation from the pancreas and also on dissolved O2 in vitro (61, 63). 
The location of beta cells—at the core of the islets of Langerhans, which are 
themselves aggregates of cells—increases the difficulty of supplying O2 to the 
core in devascularized conditions (61, 64, 65). Dionne et al. have shown that low 
O2 tension has a significant impact on the insulin secretion of islets, reporting 




low O2 pressure (pO2) of 27 mm Hg and to 2% at a very low pO2 of 5 mm Hg 
compared to islets cultured at a normal pO2 of 142 mm Hg (5% CO2, 95% air) 
(66). Scherzenmeir et al. obtained similar results, reporting a decrease in insulin 
secretion at pO2 levels below 12 to 20 mm Hg (67).  
Microencapsulation isolates islets from the surrounding environment and 
increases the diffusion barrier for O2 transport, with O2 availability and the 
quantity of dissolved O2 varying according to the site of islet transplantation, 
whether the peritoneal cavity, liver, or kidneys (61, 68, 69). Researchers have 
found that vascular structures may be developed around nonencapsulated islets 
transplanted within the first few weeks (70). However, such development is 
inhibited when islets are encapsulated using microencapsulation techniques, and 
causes chronic hypoxic stress in encapsulated conditions and allows islet O2 
transport to occur only through diffusion from the surrounding milieu instead of 
from direct supply from the bloodstream (61, 68). 
Finding the O2 pressure within the islets to be 20 to 23 mm Hg before 
isolation (71), researchers have identified hypoxic stress in the peritoneal cavity 
as the cause of decreased insulin secretion, and thus the cause of progressive 
failure of transplanted islets (72). The mean pO2 in isolated islets has been found 
to be approximately 40 mm Hg before transplantation and to decrease by a mean 
of approximately 5 mm Hg after transplantation of islets, irrespective of transplant 
site (kidney, liver, or spleen), even though the sites have significant differences in 
their blood perfusion in both diabetic or nondiabetic subjects. This finding 




their viability in transplantation conditions to avoid issues related to poor 
oxygenation or revascularization (62).  
To prevent hypoxia-related islets apoptosis, O2 carriers may be used to 
continuously provide O2 to the islets. Colton et al. designed an electrochemical 
O2 generator that continuously generates O2 by the hydrolysis of water into 
hydrogen and O2, and encapsulated an insulin-secreting cell line that 
demonstrated increased viability (73). However, this approach may not be 
suitable for microencapsulation because it involves a bulky power supply system 
and presents in vivo biocompatibility issues regarding transplantation, particularly 
the generation of O2 bubbles. A second approach, the use of highly O2-
dissolving perfluorocarbon emulsions in the encapsulated systems (74, 75), 
poses the challenges of lack of emulsion stability and lack of biocompatibility of 
the fluorocarbons, leading to concerns regarding islet toxicity. A third approach is 
the use of hypoxia-resistant islets isolated from a teleost Tilapia, which tolerates 
lower levels of O2 pressure than do mammalian islets, for encapsulation. 
However, the abundance of the islets and their long-term viability in encapsulated 
and transplanted conditions may also be a concern in this approach (76). 
 
 
1.5.1 Hb as an O2-carrying agent  
Hemoglobin (Hb) is a natural O2-carrier molecule that can be easily 
isolated from RBCs, in which it is the primary O2 carrier molecule, supplying 
more than 98% of the entire O2 supply to the tissues. Nonfunctional RBCs are 




lungs to the tissue capillaries, where it exchanges it for CO2. Hb is a polypeptide 
with a molecular weight of ~64.5 KDa composed of two alpha chains complexed 
with an iron molecule that pair with two beta chains to form a tetrameric complex 
with four binding sites for O2 molecules (77, 78). Hb loads O2 molecules at higher 
pO2 conditions in the lungs and offloads O2 molecules at lower pO2 levels. Even 
the sites of islet transplantation have low pO2 levels, which may help Hb 
molecules release O2 molecules at low pressures. The typical O2 equilibrium 
curve of Hb assumes a sigmodal shape with cooperative binding sites for O2 
molecules, i.e., the binding of one O2 molecule to Hb produces a cooperative 
effect that leads to the binding of the other three oxygen molecules (79-81).  
The objective in the design of most artificial O2 carriers is to create Hb 
with O2-carrying properties similar to those of Hb inside RBCs. However, this is 
an ambitious task because the Hb environment and the pressure within RBCs 
are different when Hb is outside the RBCs. Moreover, Hb exhibits altered 
properties and instability after isolation, having been shown to have an altered 
polypeptide complex and altered O2-binding and release properties when outside 
RBCs. Hb-O2 binding properties are also affected by pH, the presence of carbon 
monoxide (CO), and temperature. According to the Bohr Effect, at low pH, 
protons bind to a protein and change its conformation between deoxy and oxy-
state. As CO has a high binding affinity to Hb, it competes with O2 and decreases 
O2-binding capacity. Methemoglobin is a form of Hb with no O2-binding capacity 
that is used to prevent oxidation of Hb and allow it function as an effective O2 




methemoglobin content, Scherzenmeir et al. demonstrated improved functionality 
and viability of the cultured islets (67, 82).  
 
1.5.2 Rationale for Hb modification 
Isolated Hb is preferred over RBCs as an O2 carrier because it can be 
stored for a longer term and leads to fewer immunogenic problems when 
performing blood-type matching (83). However, using isolated Hb poses the 
problem of the tetrameric dissociation of Hb to dimers (32 kDa) that undergo 
glomerular filtration, causing nephrotoxicity (84). The use of heme iron in dimeric 
form, which undergoes more rapid oxidation compared to heme iron in tetrameric 
form, leads to a series of events that results in the generation of reactive O2 and 
nitrogen species, and thus results in oxidative damage (85).  
 
1.5.3 Intra- and intermolecular cross-linking 
To overcome the problems associated with their use, stroma-free isolated 
Hb molecules are modified using different approaches to increase their stability 
and molecular size. One such approach, intra- and intermolecular cross-linking, 
is a process by which isolated Hb molecules are cross-linked to form large 
molecular conjugates(86). This cross-linking can be specific or nonspecific, 
depending on the conjugating agent and the type of conjugation. Controlling the 
rate of reaction and the size of the conjugate is more difficult using nonspecific 




Intramolecular cross-linking of Hb primarily assists in stabilizing the 
tetrameric conformation and thus preventing excretion by the kidneys. The 
intramolecular cross-linker DBBF (bis(3,5 dibromosalicyl)fumarate) cross-links 
two lysine-99 residues(88, 89). Intermolecular Hb cross-linking addresses the 
problem of dimers and increases the Hb size by cross-linking intermolecularly; 
one such cross-linking agent is O-raffinose (90). One of the most extensively 
studied cross-linking agents is glutaraldehyde, which reacts with alpha amine 
groups and terminal alpha amino groups on lysine residues and cross-links both 
intra- and intermolecularly (91). However, all these approaches have failed in 
clinical trials, primarily because their use led to nitric oxide (NO)-associated 
hypertension (Table 1.2) (87). Less common approaches used in Hb stabilization 
are encapsulation (92); site-directed mutagenesis to improve specific Hb 
properties, such as resistance to peroxidases and auto-oxidation (93); and the 
use of recombinant technology to design Hb with properties similar to native Hb, 
such as the retention of physiologically relevant O2 and heme affinity (94). 
 
1.5.4 Chemistry of PEG-based cross-linking 
Poly(ethylene glycol) (PEG) is a linear or branched polymerized ether with 








Table 1.2: Chemical modifications and adverse events of hemoglobin based 
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PEG is activated at one or both ends for conjugation and functionalized based on 
the reactive group on the protein or petide. Common reactive amino acids on the 
protein include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, 
serine, threonine, tyrosine, N-terminal amino group acids, and C-terminal 
carboxylic acid. The most common route for the PEG conjugation of proteins has 
been activation of PEG with functional groups suitable for reaction with lysine. N-
terminal amino acid groups are routinely used for specific and nonspecific PEG 
conjugation by activating PEG with suitable functionalization agents, including 
acids such as COOH. One of the most prevalent amino acids, lysine, accounts 
for 10% of all amino acids in the amino acid sequencing of protein (95).  
PEG can be broadly classified into the categories of alkylating and 
acylating PEG. This study used an acylating method to randomly conjugate Hb 
with antioxidant enzymes. Active PEG is in the form of the hydroxysuccinimidyl 
esters (-OSu) structure below. 
 





















The distance between the active ester can vary up to four methylene units, 
with the length of the X units in the chain having a significant effect on the 
reactivity and hydrolysis in water. The SuO-CO-X-(CH2CH2O)n-O-X-CO-OSu 
used in this conjugation had a hydrolysis half-life of 0.75 hours (96). 
Pegylation is an approach used to stabilize or cross-link Hb molecules (97, 
98). Polyethylene glycol, the biocompatible polymer, is commercially available in 
different molecular weights and branches for conjugation with many types of 
molecules, depending on the research need (99, 100). PEG is an attractive agent 
because MP4, Hemospan ® chemically modified with monofunctional PEG-
activated with a terminal maleimide group maintains its effectiveness in hypoxic 
tissue oxygenation by preventing autoregulatory vasoconstriction (101). This 
property arises from its favorable properties, such as a large molecular excluded 
volume, high viscosity, high oncotic pressure (exerted by blood proteins by 
pulling water into circulatory system), and high O2 affinity (102). PEG-based Hb 
has recently been demonstrated to carry O2 in microcirculation and release more 
than 95% of the saturated O2 into the tissues (103). 
 
1.5.5 Importance of low-p50 (high-affinity) Hb under hypoxia 
When compared to that within the lungs, the site of Hb oxygenation, O2 
pressure in vivo is low at tissue and cellular sites (Figure 1.1) (104). This 
difference in O2 pressure leads the Hb molecule to efficiently release O2 from 
organs to tissues at the cellular level (105). When cells are prone to hypoxic 





Figure 1.1. Representation of pO2 differences from the airways to the cytosol, 
modified and adapted from (104). 
 
 
release a greater quantity of O2 (106). One such carrier would be a low-p50 Hb-
based O2 carrier that helps release relatively large amounts of O2 at low 
pressures under hypoxic conditions (107). Low-p50 Hb, which has a high affinity 
for O2, binds O2 in circulation and allows O2 release in only O2-deficient hypoxic 
conditions, protecting cells from hypoxic stress. By the differential expression of 
Hb macromolecules of higher and lower O2 affinity (108), the crustacean species 
Daphnia magna has developed a tolerance to hypoxia that has allowed it to 
adapt to extreme environments with limited O2 availability.  
 
 
1.5.6 O2 carriers and buffering capacity 
 
O2 carriers carry and release O2 passively by equilibrating with the 










where n is the cooperativity and p50 is the pO2 saturation level at which 
saturation is equal to half the normal level. Outside the binding range, the O2 
carrier is either fully oxygenated above a partial level of O2 saturation or fully 
deoxygenated below the lower limit, and any change in the surrounding partial 
O2 pressure will not change its O2 saturation. Hb-based O2 carriers are not O2 
pumps, and will only equilibrate with the surrounding partial O2 pressure by 
replacing the consumed O2 saturation. Hb-based O2 carriers are not O2 pumps, 
and will only equilibrate with the surrounding partial O2 pressure by replacing the 
consumed O2.  
Thus, the buffering capacity of O2 carriers, which is the ratio of change in 
partial O2 saturation to partial O2 pressure, is determined by the sensitivity of the 
carrier to the gradient changes of surrounding pO2 (109). For example, Hb 
saturation varies between 10% and 70% when pO2 increases from 7 to 40 mm 
Hg (~1% to 6% O2) for p50 of 24.5 mm Hg and n = 1.75 but between 78% and 
95% in myoglobin for 2 mm of p50 mm Hg and n = 1, indicating that O2 carriers 
act as better buffering agents near their p50 value and demonstrating the greater 
effectiveness of Hb than myoglobin for hypoxic transplantation conditions of 1% 
to 6% O2. Due to the absence of cooperativity, myoglobin has a lower buffering 













 During increased O2 demand by cells, cell-free Hb assists in the formation 
or re-occupation of replaced O2 by facilitating O2 transport by diffusion through 
plasma. The rate of diffusion (translational) in O2 carriers through liquid has been 
shown to be inversely proportional to the viscosity of the medium and the size of 
the carrier, and thus isolated Hb-based O2 carriers are able to replace O2 more 
rapidly than are RBCs (109). In cell-bound O2 transport, the normal physiological 
decrease in O2 from the lung to the tissue level helps deliver higher amounts of 
O2. In cell-free Hb, low p50 and facilitated diffusion assist in O2 re-saturation and 
delivery in hypoxic conditions (110). 
Cell-free Hb increases the solubility of O2 and decreases the resistance to 
O2 diffusion by constantly exchanging O2 between the Hb and O2 dissolved in 
media. O2 delivery in normoxic tissues has been shown to be relatively 
insensitive to p50 values for O2 delivery. However, values below 15 Torr can 
increase O2 unloading in hypoxic conditions when Hb p50 is lowered (high-
affinity). Increased O2 cooperative binding increases O2 delivery, even in cases 
of substantially reduced delivery. In one study, cell-free sebacyl cross-linked Hb 
supported intestinal function under hypoxic conditions, while an equivalent 
quantity of Hb inside RBCs provided poor support (110). 
 
1.6 Effect of ROS (reactive oxygen species) on islets and Hb 
  Free radicals are species or molecular fragments that have one or more 
unpaired electrons. Potential endogenous sources of free radicals include 




neutrophils, eosinophils, and macrophages. Exogenous processes or substrates, 
such as radiation; carcinogens; chlorinated compounds; and redox metal ions, 
such as iron, generate ROS either directly or indirectly (111, 112). The most 
common ROS are the superoxide anion (O2·-), the hydroxyl radical (OH·), and 
H2O2, which are generated intracellularly by different subcellular processes, and 
eventually cause lipid peroxidation and cell death (113). Superoxide anions are 
formed when an O2 molecule acquires an additional electron, leaving it with an 
unpaired electron. Hb that undergoes oxidation by peroxide and auto-oxidation 
by endogenously produced oxidants produces methemoglobin, which has an 
oxidation state of +3 and cannot effectively bind to O2. The iron catalyzation that 
occurs in Hb by superoxide according to the Fenton reaction and the Haber-
Weiss reaction can produce damaging short-lived hydroxyl radicals (Table 1.3) 
(112). Furthermore, the methemoglobin produced releases heme more readily 
than does its ferrous counterpart, increasing the potential for iron-mediated free-
radical toxicity (114). In RBCs, methemoglobin is maintained at a level less than 
1% of total Hb (115) by the intrinsic reductive mechanisms of the Embden-
Meyeroff pathway and the pentose phosphate pathway (117, 118). Post 
transplantation, islets are prone to stress, and undergo apoptosis due to the 
presence of free radicals (119), NO (120),  interleukin-1 (121), interferon-γ, tissue 
necrosis factor-alpha (122), and other ROS that are released due to the 
activation of immune cells and macrophages or because of glucose-catalyzed 
oxidative stress (123). In addition, insulin-secreting cells, such as pancreatic 




Table 1.3: Free-iron-catalyzed oxidation reactions on Hb, modified and adapted 
from (116). 
Iron catalyzed oxidation reactions on Hemoglobin 
Fenton reaction 
H2O2 + Fe (+II) →   Fe (+III) + OH- + OH· 
O2·- + Fe (+III) → Fe (+II) + O2 
 
Haber-Weiss reaction 
O2·- + H2O2 → O2 + OH- + OH· 
 
Oxidation of oxyHb by hydrogen peroxide 
HbFe (+II) O2 + H2O2 →    HbFe (+IV) =O +H2O +O2 
Auto-oxidation of Hb 
HbFe (+II) O2    → HbFe (+III) +   O2·- 
 
Direct reduction of oxygen by ferrous iron 
Fe (+II) + O2 →   Fe (+III) + O2·- 
Hydroxyl radical generation from heme-free iron and hydrogen peroxide 
Fe (+II) + H2O2   → Fe (+III) + OH- + OH· 
 
 
superoxide dismutase (SOD) and catalase (CAT), that assist in the removal of 
superoxide anions and H2O2, making islets prone to free-radical-induced 
oxidative damage (124, 125).  
Several genetic and chemical modifications have been proposed as 
means of enhancing the resistance of insulin-secreting cells to oxidative stress. 
Recently, hemeoxygenase-1 (HO-1) (126), an anti-oxidant enzyme expressed by 
chemical treatment of islets, was reported to protect islets from radical 
scavenging and aid in apoptosis prevention. Protection of islets from oxidative 




islets, with a coencapsulation approach using cross-linked Hb-Hb having been 
found effective in preventing an NO attack in vitro (100). 
 
1.7 Antioxidant enzymes  
The most efficient enzymatic antioxidants include superoxide dismutase 
(SOD), catalase (CAT), and glutathione peroxidase. Nonenzymatic antioxidants 
include vitamin C; vitamin E; carotenoids; thiol antioxidants, such as glutathione, 
thioredoxin, and lipoic acid; natural flavonoids; and melatonin, a hormonal 
product of the pineal gland (112). Researchers have used many antioxidant 
molecules, such as vitamin C, heme oxygenase, vitamin E, SOD, CAT, and 
many other chemically synthesized compounds, to help prevent free-radical- 
mediated cell death (113).  
 
1.7.1 Superoxide dismutase 
Appearing in one of three forms, SOD (32 kDa) is a group of metal-
containing enzymes that catalyze the reduction of a superoxide radical to H2O2 
and O2 (Table 1.4).  
Two forms of SOD, copper/zinc SOD (Cu/Zn-SOD), which is present in the 
cytoplasm, and manganese SOD (Mn-SOD), which is present in the 
mitochondria, are intracellular, while the third form, extracellular SOD (EC-SOD), 
is, as indicated by its name, extracellular, and contains Cu and Zn at its active 
site. This study used bovine erythrocyte SOD, a type of intracellular Cu/Zn-SOD 




Table 1.4: Mechanism of SOD and CAT protection, modified and adapted from 
(127). 
 
Superoxide dismutase Catalase 
Reaction 
2O2
·- + 2H+ → H2O2 + O2 
 
Reaction 












→ SOD-Cu+ + O2 
SOD-Cu+ + O2
·- + 2H+  → SOD-Cu+2  
                                  + H2O2 
 
CAT-Fe+3  + H2O2
 




· + H2O2→ CAT-Fe+3  
                              + H2O + ½ O2 
 
 
acids, with each subunit containing 10 free lysines available for modification. 
Cu/Zn-SOD contains seven conserved His residues that play an important role in 
enzymatic activity and an “electrostatic loop” that contains four highly conserved 
charged residues (Lys120, Glu130, Glu131, and Lys134) that promote the 
catalytic action by attracting and directing superoxide anions toward the Cu site 
(127). 
 
1.7.2 Catalase  
CAT is an intracellular tetrameric enzyme with four subunits, each bearing 
one ferric protoporphyrin in the prosthetic group (128), that catalyzes the 
breakdown of H2O2 to H2O and O2 (112). Regarding the enzyme catalysis, which 
is shown in Table 1.4, cross-linking has demonstrated that there is no loss in the 




the enzyme’s active site (129). The CAT active site structure includes a heme 
molecule; distal His-54 and Asn-127, which are involved in H2O2 binding; and 
proximal Tyr-337, which binds to the proximal heme iron ligand and His-341(130, 
131). 
 
1.8   Summary of current challenges in using the BAP  
• Islet scarcity 
• Lack of encapsulating membrane compatibility 
• Complete immunoisolation 
• Lack of cell viability 
• Lack of oxygen supply (hypoxic stress) 
• Free radical stress 
The remaining sections of this work focus on addressing the last two problems. 
 
1.9   Proposed research strategy 
Previous studies (PEG-conjugated Hb with SOD and CAT) found that 
encapsulation of PEG cross-linked Hb increased the insulin secretion of islets by 
increasing the O2 supply (132). However, insulin secretion was sustained for only 
about three months, both in vivo and in vitro (99, 132). Even when Hb can supply 
O2 to the encapsulated islets, it is prone to oxidation by conversion of Hb to 
methemoglobin. To prevent this deleterious oxidation reaction and thus enhance 
O2 delivery to tissues, an effective Hb protection mechanism is required. The 




SOD and CAT (133, 134), with Hb has been proposed as means of overcoming 
the dual problems of Hb oxidation and free-radical-mediated islet apoptosis. SOD 
and CAT are abundantly present in RBCs, where they serve as the primary 
antioxidants in protecting Hb from oxidative damage. As they work together, both 
enzymes must be microencapsulated to provide for effective protection of islets 
(Figure 1.2). SOD has been shown to decrease the Hb oxidative process by 
31%, CAT to decrease it by 53%, and SOD and CAT together to decrease it by 
76% (135, 136). Hypoxic conditions near the islets, such as that created by 
oxygen pressure below 40 mmHg at an implantation site, lead to a decrease in 
pH, decreasing the affinity of Hb for O2 and release a large quantity of O2 or 
unload O2 as pO2. An antioxidant-enzyme approach using low p50 PEG-based 
O2-carriers has been proposed to enhance unloading of O2 in large quantities 
below the p50 of the carrier under hypoxic (low O2) conditions.The results 
obtained from this proposed research approach will assist in determining the 
capacity of O2-carrying conjugates to deliver O2 to the islets at implantation sites 
under conditions of hypoxia and the resulting hypoxia- induced free-radical 
environment. This approach has been shown to be partially successful in 
previous studies using only Hb (99, 137). This study attempted to confirm 
previous findings regarding the capacity of conjugates with low p50 to supply O2, 
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2. SYNTHESIS AND CHARACTERIZATION OF HEMOGLOBIN  
CONJUGATES WITH ANTIOXIDANT ENZYMES  
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Nadithe, V., and Bae, Y. H. (2010) Synthesis and characterization of hemoglobin 
conjugates with antioxidant enzymes via poly(ethylene glycol) cross-linker (Hb-

















Employing dicarboxymethylated poly(ethylene glycol) to conjugate Hb with 
antioxidant enzymes has been proposed for a means of providing enhanced 
protection to Hb against free radicals. This study examined the effectiveness of 
this conjugation process employing SDS-PAGE and SEC techniques to produce 
Hb-SOD-CAT conjugates of an estimated average molecular weight of 1000 kDa. 
When incubated with H2O2 (0.1 and 1mM) and xanthine (1mM)/xanthine oxidase 
(10 and 20mUnits/mL), the conjugates were found to retain greater than 70% to 
90% of their original bioactivity. During the conjugation process and over one 
month of storage at 4 ºC, the antioxidant enzymes were found to minimize 
methemoglobin formation. Based on the results, the study concluded that 
optimized (1:10 Hb:PEG) cross-linked conjugates with antioxidant enzymes 
provide cells with protection from severe free-radical stresses (Scheme 2.1). 
 




Cell-free Hb has been widely investigated as an artificial O2 carrier to treat 
conditions such as hemorrhagic shock (1), anemia (2), and ischemia (3) by 
means of blood transfusion. However, cell-free Hb is unstable, and the tetramer 
dissociation is known to cause nephrotoxicity (4). Vasoconstriction, another 
problem with using cell-free Hb, has been a primary reason for its failure as an 
O2 carrier in many clinical trials (5). Fortunately, a number of different 
approaches, including cross-linking (6), polymerization (7), the use of 
recombinant technology (8), and encapsulation (9, 10), have shown very 
promising results in stabilizing tetrameric Hb. Stabilizing Hb by these approaches 
has been shown to help deliver O2 efficiently in blood transfusions and other 
treatments under conditions of normal O2 pressure within the body. However, 
most of these approaches only stabilize the alpha and beta tetramers of Hb, and 
do not offer much protection from auto-oxidation (11) or free radicals, such as 
hydroxyl and superoxide anions (12). Inside RBCs, high levels of antioxidant 
enzymes, such as SOD and CAT, assist in the protection of Hb from free-radical 
damage (13). To have a protective effect in the above oxidation conditions, an 
Hb-based O2-carrier system with an antioxidant defense mechanism that can 
protect itself from both hypoxia-induced free radicals and environmental radical 
stressors to preserve Hb O2-carrying capability is required (14).  
Although glutarladehyde cross-linking has been shown to stabilize 
hemoglobin, increasing the glutaraldehyde-to-hemoglobin molar ratio above 40:1 
increases the methemoglobin content (15). The addition of antioxidant enzymes 
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has been demonstrated to reduce oxidation (16), but the release of 
glutaraldehyde by degradation of the polymeric link and its associated toxicity 
remains a significant concern (17). The promotion of vasoconstriction by the NO-
scavenging of glutaraldehyde-cross-linked products from the vasculature is also 
a serious concern (18, 19). It is therefore highly desirable to design a cross-
linking reagent that is of low cytotoxicity and high biocompatibility.  
One approach, the use of PEG-based modified polymers, has shown to 
reduce hypertensive responses and the NO-scavenging effect, and thus inhibit 
vasoconstriction. These effects may be attributed to the beneficial effects 
associated with PEG polymers, such as an increase in molecular size and 
hydrodynamic volume (20). Extensive literature has described approaches using 
PEG in proteins for pharmaceutical applications as useful and safe, as well as 
appropriate for conjugating Hb. The molecular weight of PEG used in the 
conjugates is important, as the use of Hb modified by PEG of low molecular 
weight has been shown to decrease the vasoconstrictive effect to a greater 
extent than the use of PEG of high molecular weight (21). PEG-modified Hb has 
been shown to offer the unique advantages of low cooperativity and high O2 
affinity or low p50 (20, 22). It has also been reported that cysteine modification of 
Hb using PEG-malemide chemistry increases Hb auto-oxidation and enhances 
oxidation by PEG chains in the presence of H2O2 (23). 
Previous research by the authors of this paper has shown that cross-
linked Hb improves the functionality of encapsulated isolated pancreatic beta 
cells in transplanted diabetic mice by maintaining O2 supply to encapsulated cells 
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(24, 25). However, the viability of Hb is limited due to its eventual conversion to 
methemoglobin and the free-radical damage that is sustains from auto-oxidation. 
To overcome these problems in a manner in accordance with the most recent 
literature, this study investigated the use of polyethylene glycol, SOD, and CAT 
to conjugate the available amino groups (lysine, arginine, asparagine, glutamine, 
and histidine) on Hb. Although polymerization can stabilize Hb, the addition of 
SOD and CAT may be a better strategy, provided the enzymatic actions inhibit 
the conversion of Hb into methemoglobin. This particular conjugate design may 
also help protect Hb from oxidation during chemical conjugation, auto-oxidation, 
and free radical stress during storage in a size suitable for co-encapsulation with 
isolated islets for cell transplantation.  
 
 
2.3 Experimental section 
2.3.1 Material 
Freshly pooled bovine RBCs were purchased from Innovative Research 
(Novi, MI IC100-0410). Polyethylene glycol (molecular weight: 2 kDa), 
superoxide dismutase from bovine erythrocytes (SOD-S7571), bovine liver 
catalase (CAT-C40), tertiary butoxide, ethyl bromoacetate, N-Hydroxy-
succinimide (NHS), N,N′-dicyclohexylcarbodiimide (DCC), hydrogen peroxide 
(H2O2), xanthine, and xanthine oxidase (XO) were purchased from Sigma 
Chemical Co. (MO, USA). Dialysis membranes were purchased from spectrum 
labs (Rancho Dominguez, CA). Amicon Ultra-15 Centrifugal Filter Units, 50 and 
100 kDa, were purchased from Millipore Corporation (Billerica, MA). 
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2.3.2 Hb isolation 
Briefly, freshly withdrawn bovine RBCs were washed twice with normal 
saline solution by centrifuging at 2500 rpm for 20min to isolate the Hb. The Hb 
was extracted from the washed RBCs by mixing the substrate with 4:1 water and 
dichloromethane and shaking it for 5min. Released Hb that partitioned into the 
aqueous phase was collected by further centrifuging at 2500 rpm for 20min. The 
process was repeated twice and the isolated Hb centrifuged to remove any 
remaining organic solvent. The isolated Hb was dialyzed for 48h using a 50 kDa 
dialysis membrane, then transferred to a 100 kDa dialysis tube and dialyzed for 
24h such that only pure Hb diffused out, which was further concentrated using 
Amicon membranes. The purity of the Hb was verified by sodium dodecylsulfate-




2.3.3 PEG modification 
PEG (2 kDa) was customized for conjugation by employing previously 
reported methods (24, 26, 27). Briefly, the hydroxyl group of PEG was converted 
to ethyl-protected carboxymethylated PEG using potassium tertiary butoxide and 
ethyl bromoacetate. Hydrolysis of the product using sodium hydroxide resulted in 
a mixture of carboxylic (mono and di) PEG, which was further purified by ion-
exchange chromatography. The product was converted to NHS-active ester 
using DCC and NHS to yield PEG-NHS, which was used for the conjugation of 





Scheme 2.2. Representation of cross-linking Hb with SOD and CAT employing 
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activated PEG diacid into NHS, it was characterized by 1H NMR spectroscopy 
and thin-layer chromatography.  
 
 
2.3.4 Hb conjugation with SOD and CAT  
To produce Hb-only conjugations, isolated bovine Hb was conjugated with 
PEG by varying the Hb:PEG molar ratio between 1:5 and 1:30. To produce Hb 
conjugations with SOD and CAT, Hb:PEG ratios identical to those used in Hb-
only conjugations were used, and the ratio between SOD and CAT was fixed 
between 30000 to 300000 enzyme units in all conjugation reactions (24, 28). All 
Hb conjugation reactions in the PBS buffer (pH 7.4 with and without SOD and 
CAT) were conducted by adding activated PEG and stirring for 3h at 4 °C. 
Unreacted PEG and protein components were removed using 100-kDa dialyzing 
membranes and changing the PBS buffer for 24h. The product was further 
concentrated to the desired concentration using Amicon centrifugation filters, 
filter sterilized using a 0.22-µm pore size syringe filter, and stored at 4 °C until 




 Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 
PEG-conjugated Hb with and without SOD and CAT was performed on 4% to 
12% Bis-Tris NuPAGE gels under reducing conditions by employing the XCell 
SureLock Mini-Cell apparatus (Invitrogen Life Technologies, Carlsbad, CA). The 
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samples were heated (denatured) at 70 °C for 10min before 1-to-10-μg-
equivalent Hb protein was (20μl volume) applied to the gel. Electrophoresis was 
conducted at a constant 150 V for approximately 90min. The SeeBlue Plus2® 
prestained molecular weight standard was added to all gels and separation 
achieved using the NuPAGE® MES SDS running buffer in accordance with the 
manufacturer’s (Invitrogen’s) instructions. In order to observe the products, the 
gels were rinsed with ultrapure water (Millipore) and stained by SimplyBlueTM 
safe stain (Invitrogen), followed by extensive washing in pure water for protein 
detection. The completion of the conjugation process was assessed by 
comparing it with appropriate molecular weight standards.   
 
 
2.3.6 Size exclusion chromatography analysis of conjugates 
Size exclusion chromatography (SEC) was performed employing the 
Agilent 1100 Liquid chromatography separation system for determining the 
weight-average molecular weight with absorbance detection at 280 nm (Agilent 
Technologies, Santa Clara, CA). The separation was performed on a BioSEP-S-
4000 column (hydrophilic-bonded silica of 5-µm particle size and 500 Ao pore 
size) capable of resolving high-molecular- weight proteins ranging in size from 15 
kDa to 2000 kDa (Phenomenex,Torrance, CA). The column was equilibrated 
using the mobile phase (0.1 M potassium phosphate buffer, pH 7.4).Samples 
were diluted in PBS and separated through the column at a flow rate of 0.5 
ml/min at room temperature. Fifty microliters of cross-linked Hb-Hb and Hb-SOD-
CAT conjugate solutions were injected, and the molecular weight of the samples 
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determined from a standard curve derived from the retention times of protein 
reference standards using the Sigma molecular mass marker. Molecular 
standards include carbonic anhydrase (29 kDa), bovine serum albumin (66 kDa), 
alcohol dehydrogenase (150 kDa), beta-amylase (200 kDa), apoferritin (443 
kDa), thyroglobulin (669 kDa), and Dextran Blue (2000 kDa). All the data were 
analyzed using Agilent Chemstation software. The molecular weights and their 
distributions by SEC were represented and described in accordance with Hu Tao 
(29) and Nonier MF (30). 
 
 
2.3.7 Analysis of absorption spectra of conjugated Hb 
Employing a UV-visible SpectraMax spectrophotometer (CA, USA), the 
qualitative analysis of conjugated Hb was conducted by measuring the visible 
absorption spectrum of conjugated Hb with and without SOD and CAT. Twenty-
µM Hb conjugates was placed in a UV cuvette and the visible absorption 
spectrum was scanned between 450 and 750 nm for 2 seconds. 
 
 
2.3.8 Methemoglobin quantification 
 The quantity of methemoglobin in conjugated samples was determined 
using a method described by Patton et al. (31). Briefly, a sufficient quantity of the 
conjugated protein was placed in a UV-visible cuvette and diluted such that it 
provided an absorbance of less than one unit at 630 nm, referred to as A1. This 
value corresponded to the total Hb content, which consisted of oxy-, deoxy-, and 
methemoglobin content, in the sample. The sample was then treated with one 
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drop (50 μL) of potassium cyanide solution (1 part 10% KCN and 1 part PBS pH 
7.5) and allowed to react for 5 to 10min. A second absorbance measurement 
referred to as A2 was performed on the same sample at 630 nm. The difference 
between A2 and A1 was calculated, and the methemoglobin content in the 
samples was calculated using the extinction coefficient value for methemoglobin 
(3.7 cm mM)-1. The total Hb content in the sample was measured by placing the 
same quantity of conjugates in another cuvette and adding one drop (50 μL) of 
20% K3Fe(CN)6 with a dilution. After the conversion of the oxy- and deoxy-Hb in 
the sample into methemoglobin, another drop of 10% KCN was added and the 
absorbance peak at 540 nm was measured (A3). Using the extinction coefficient 
of 11 (cm mM)-1 for cyanomethemoglobin, the Hb content was calculated using 
the equation below, and the percentage of methemoglobin was calculated from 

















2.3.9 SOD enzymatic assay  
The level of SOD activity was determined using a previously reported 
cytochrome C reduction assay method (32-34). Specifically, SOD activity was 
measured by determining the rate of reduction of cytochrome C inhibition by the 
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superoxide radical generated using a xanthine and xanthine oxidase system at 
pH 7.8 and room temperature. The samples contained a mixture of 50 mM of 
potassium phosphate, 0.01 of mM cytochrome C, 0.1 mM of 
ethylenediaminetetraacetic acid, 0.05 mM of xanthine, 0.005 units of xanthine 
oxidase, and conjugated Hb. The uninhibited rate of reduction was adjusted by 
changing the quantity of the xanthine oxidase enzyme used in the assay such 
that the reaction produced an initial change in the absorbance between 0.025 - 
0.005 per min at 550 nm. A 50% rate reduction of cytochrome C in the inhibited 
samples was considered to correspond to one unit of SOD. The background 
activity by the Hb component in the antioxidant-conjugated samples was 
subtracted by assaying equivalent activity in Hb-only conjugated samples. The 
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2.3.10  CAT enzymatic assay 
CAT activity was measured by monitoring the decomposition rate of H2O2 
at 240 nm (35-37). Specifically, CAT was assayed in the conjugates by 
measuring the enzyme-catalyzed decomposition rate of H2O2 in accordance with 
the Sigma-Aldrich test procedure for the enzymatic assay of CAT (Sigma Aldrich, 
EC 1.11.1.6). A fresh 0.036% (w/w) H2O2 solution was prepared in 50 mM of 
potassium phosphate buffer at pH 7.0 and room temperature such that its initial 
absorbance was 0.550 units. 2.9 ml of this reagent was mixed with 0.1 ml of 
conjugated proteins in a cuvette, and the time required for a reduction in 
absorbance from 0.45 to 0.40 absorbance units was calculated. The number of 
enzyme units in the sample was calculated as per the equation below. 
 
sample) enzyme of (0.1ml  0.40  to0.45 from 
absorbancein  decreasefor  minutesin  Time












The value of 3.45 in the equation refers to the decomposition of 3.45 μM 
of H2O2 in a 3.0-ml reaction mixture that decreases the absorbance from 0.45 to 
0.40 absorbance units. The background activity of Hb in the samples was 
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removed by calculating the equivalent Hb activity in conjugated samples without 
SOD and CAT. 
 
2.3.11 Combined peroxide and superoxide challenge 
To examine the protective effect of Hb in Hb-antioxidant enzyme 
conjugates, the 1:10 Hb-Hb and Hb-SOD-CAT conjugates were tested by 
challenging them with superoxide anions generated by a xanthine 
(1mM)/xanthine oxidase (10 and 20 mUnits/mL) system and H2O2 (0.1 mM and 1 
mM), both of which generate hydroxyl free radicals. Twenty μM of Hb equivalents 
were used in every reaction that had been incubated with free radicals for 30 
min, 3 h, 24 h, and 48 h at room temperature in UV-visible cuvettes. The 
protective effect of Hb and its conversion to non-O2-binding methemoglobin was 
evaluated using UV-visible spectrophotometry. 
 
 
2.3.12 Statistical analysis 
The statistical significance of the difference between conjugated Hb with 
and without SOD and CAT was analyzed by performing one-way analysis of 
variance (ANOVA) testing followed by Holm-Sidak testing to compare group 
means for differences between enzymatic activity and polymer conjugation ratios 
and to determine the conjugation and storage effect on methemoglobin 
formation. For all analyses, a p value less than 0.05 was considered to indicate 






2.4 Results  
2.4.1 SDS-PAGE 
The results of SDS-PAGE analyses indicated the formation of cross-linked 
products at all Hb:PEG ratios (1:5, 1:10, 1:15, 1:20, and 1:30) both with and 
without SOD and CAT. A range of different molecular weight conjugates were 
obtained (~100 kDa products and >180 kDa) when compared to the molecular 
weight standards used in SDS-PAGE (Figure 2.1). The smear-like or ladder-like 
appearance of the SDS-PAGE results indicates the differential mobility of the 
conjugates due to differences in the sizes/molecular weights of the polymerized 
conjugates. However, SDS analysis demonstrated only the formation of the 
polymerized products, and did not specify the exact size of the conjugates with 
molecular weights above the detection limit of 180 kDa. The results of these 
analyses provided the first piece of confirming evidence regarding the cross-
linking of Hb-Hb and Hb-SOD-CAT conjugates. 
 
 
2.4.2 SEC analysis of conjugates 
SEC analysis confirmed the formation of large PEG cross-linked Hb 
conjugates both with and without SOD and CAT with a broad elution spread in all 
Hb:PEG molar ratios (Figure 2.2). When Hb-only conjugates were polymerized  
employing PEG, a heterogeneous population of cross-linked Hb was obtained 
with molecular weights ranging from ~150 kDa to ~2000 kDa. The chromatogram  
shows more prominence toward the lower retention times (the left side) than 
 






Figure 2.1. Sodium dodecylsulfate-polyacrylamide gel electrophoresis showing 
formation of Hb cross-linked products with and without SOD and CAT (Hb:PEG). 
Lane A, 1:5 Hb-Hb; Lane B, 1:10 Hb-Hb; Lane C, 1:15 Hb-Hb; Lane D, 1:20 Hb-
Hb; Lane E, 1:30 Hb-Hb; Molecular Weight Standard; Lane F, 1:5 Hb-SOD-CAT; 
Lane G, 1:10 Hb-SOD-CAT; Lane H, 1:15 Hb-SOD-CAT; Lane I, 1:20 Hb-SOD-




majority of the cross-linked Hb-only conjugates were comprised of a high 
molecular weight species of ~2000 kDa. Different Hb/PEG ratios yielded similar 
molecular weight distribution profiles. When SOD and CAT were added during 
cross-linking, the chromatograms of the conjugates show a molecular weight 
ranging from ~100 kDa to ~1500 kDa. However, chromatograms of Hb 
conjugates with SOD and CAT show a major peak shift toward higher retention 
times of ~100 kDa time (the right side), unlike Hb-only conjugates. Minimal 







Figure 2.2. SEC of cross-linked Hb with and without SOD and CAT of Hb-PEG 
ratios from 1:5 to 1:30 and a SOD-CAT enzyme ratio of 30000:300000 units. 
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including among those conjugates with SOD and CAT. The average molecular  
weight for all the conjugates appeared to range from ~800 to 1000 kDa, with 
broad peak profiles and dramatic differences in elution profiles for the 
conjugation of Hb with and without SOD and CAT.  
 
 
2.4.3 Visible absorbance spectra of conjugated Hb 
 Oxyhemoglobin has two characteristic absorbance peaks at 540 and 
575 nm and appears red in the solution state, whereas methemoglobin has one 
characteristic peak at 630 nm and appears dark brown. As shown in Figure 2.3, 
when Hb was self-cross-linked, an increased quantity of methemoglobin 
formation resulted with increasing amounts of the cross-linking agent PEG. The 
change in absorbance was found to vary from 0.01 to 0.2 units when Hb was 
self-cross-linked at Hb:PEG molar ratios between 1:5 and 1:30. A significant 
change in the absorbance at 630 nm was observed at Hb:PEG cross-linking 
ratios of 1:15, 1:20, and 1:30. However, the addition of SOD and CAT during 
cross-linking significantly decreased the formation of methemoglobin, as 
demonstrated by the lower absorbance at 630 nm. This decrease is clearly 
significant up to a 1:20 Hb:PEG ratio with SOD and CAT, with only a slight 
increase observed at a 1:30 Hb:PEG ratio. The change in absorbance varied 






Figure 2.3.  Absorbance spectra of cross-linked Hb with SOD and CAT 24h after 
cross-linking, Hb:PEG ratios 1:5 to 1:30 and SOD/CAT enzyme ratio of 
30000:300000 units.  
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2.4.4 Methemoglobin quantification 
As shown in Figure 2.4, the cross-linking of Hb by PEG enhanced the 
conversion of Hb to methemoglobin in the absence of antioxidant enzymes. For 
self-cross-linked Hb, the methemoglobin content increased within one day 
when an increasing quantity of PEG-conjugating agent was added. This 
increase was greater than 10% for an Hb:PEG ratio of 1:15 and greater than 
40% for ratios of 1:20 and 1:30. Such Hb-only conjugates are unlikely to be 
useful as O2 carriers due to the large quantity of methemoglobin unless a 
mechanism to reverse this process can be incorporated. One such mechanism 
may be the addition of antioxidant enzymes, which in this study led to a 
significant decrease in the quantity of methemoglobin at all Hb:PEG ratios 
during cross-linking. The complete absence of methemoglobin in Hb 
conjugates with SOD and CAT was observed at Hb:PEG ratios of 1:5, 1:10 and 
1:15, and only 1.6 ± 0.6% was observed at the 1:20 ratio and 7.3 ± 1.3% at the 
1:30 ratio. These results indicate that the conjugating agent had a significant 
effect on the methemoglobin content, emphasizing the need for the addition of 
antioxidant enzymes to inhibit the conversion of Hb to methemoglobin. 
Although methemoglobin is formed in all cross-linking without antioxidants, the 
results of statistical analysis indicated significant differences between Hb-only 
and Hb-SOD-CAT cross-linked formulations only at Hb:PEG ratios of 1:15, 




Figure 2.4. Effect of SOD and CAT on methemoglobin formation in cross-linked 
Hb during storage at 4 0C for one month, with Hb:PEG ratios 1:5 to 1:30 and a 




 The results also indicate that self-cross-linked Hb conjugates stored at 4 
0C for one month will develop methemoglobin content of more than 10%. A 
significant increase of methemoglobin was observed at Hb:PEG ratios of 1:5 
(from 2.2 ± 0.1% to 10 ± 1.2%), 1:10 (3.4 ± 0.6% to 16.6 ± 1%), and 1:15 (14.6 
± 0.5% to 21.4 ± 1.5%). The results of statistical analysis also indicated a 
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Hb/PEG ratios (1:5 to 1:30) of cross-linked Hb at days 1 and 30 without SOD 
and CAT (p-value < 0.001). However, for cross-linked Hb with SOD and CAT, 
the percentage of increase in methemoglobin content was less than 10% in 
Hb/PEG ratios of 1:5, 1:10, 1:15, and 1:20, with only the ratio of 1:30 showing 
an increased methemoglobin content (from 7.3 ± 1.3% to 15.52 ± 2.1%). These 
results provide evidence for the beneficial effect of the addition of SOD and 




2.4.5 Retention of SOD enzymatic activity 
 For the effective removal of superoxide anion free radicals and the 
protection of Hb from free radicals, the enzymatic activity of conjugated SOD 
must be preserved after cross-linking with PEG and Hb in the final conjugate mix. 
The results show that the enzymatic activity of the conjugated SOD was reduced 
in comparison to the enzymatic activity of the control (free) SOD (Table 2.1). 
However, the enzymatic activity of SOD in all the conjugates was shown to be 70 
to 80% of the original. Although the enzymatic activity decreased compared to 
the enzymatic activity of the control SOD, there was no statistically significant 
differences among the conjugated Hb with SOD at different PEG ratios (p = 
0.154). This indicates that increasing the quantity of the PEG used in conjugation 






Table 2.1. Percentage retention of SOD enzymatic activity in Hb conjugates after 
cross-linking with modified PEG  
 
 
Conjugate (Hb:PEG) SOD enzymatic activity
 a) 
Percentage retained b) 
Hb-SOD-CAT (1:5) 73 ± 2 
Hb-SOD-CAT (1:10) 79 ± 3 
Hb-SOD-CAT (1:15) 76 ± 6 
Hb-SOD-CAT (1:20) 72 ± 5 
Hb-SOD-CAT (1:30) 67 ± 5 
 
a) Based on the enzymatic activity of free SOD added before conjugation; b 




2.4.6 Retention of CAT enzymatic activity  
          For the effective removal of peroxide free radicals in the protection of Hb 
from free radicals, the enzymatic activity of conjugated CAT must be preserved 
after cross-linking with PEG in the final conjugate mix. As shown in Table 2.2, the 
enzymatic activity of conjugated CAT is similar to the enzymatic activity of free 
CAT (the control). The CAT activity of all the conjugates was estimated to be 
between 90 and 99%. Increasing the quantity of PEG polymers for conjugating 
Hb with CAT resulted in no statistically significant differences in enzymatic 




Table 2.2. Percentage retention of CAT enzymatic activity in Hb conjugates after 
cross-linking with modified PEG  
 
Conjugate (Hb:PEG) CAT enzymatic activity
 a) 
Percentage retained b) 
Hb-SOD-CAT (1:5) 91 ± 6 
Hb-SOD-CAT (1:10) 93 ± 2 
Hb-SOD-CAT (1:15) 96 ± 3 
Hb-SOD-CAT (1:20) 91 ± 4 
Hb-SOD-CAT (1:30) 90 ± 4 
 
a) Based on the enzymatic activity of free CAT added before conjugation; b 




2.4.7 Protection of Hb from H2O2  
Challenging Hb-only conjugates (Hb/PEG 1:10 molar ratio, 20 µM) and 
Hb-SOD-CAT conjugates with H2O2 (0.1mM and 1mM) for 0.5, 3, 24, and 48h 
led to identification of a significant protective effect on cross-linked Hb with 
SOD and CAT, as shown in Figures 2.5 and 2.6. When Hb-only cross-linked 
conjugates were challenged with 1 mM of H2O2, the absorption peak for 
methemoglobin appeared within 30min of incubation, with the increase in 
absorbance at 630 nm being approximately 0.11 units at 30min and 0.15 units 
at 48h. The corresponding characteristic Hb absorbance peak decrease was 
found to be 0.33 (30min) and 0.46 (48h) units at 540 nm, and 0.37 (30min) and 
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Hb-Hb (1:10)  Control 
Hb-Hb (1:10)  (0.1mM H202) 
Hb-Hb (1:10)  (1mM H202) 
HB-SOD-CAT (1:10)  Control 
HB-SOD-CAT (1:10)  (0.1mM H202) 
HB-SOD-CAT (1:10)  (1mM H202) 
  (30 mins) Absorbance Change at        540nm           575nm           630nm
Hb-Hb (Hb-SOD-CAT) a     0.27 (0.04)   0.31 (0.05)   0.08 (0.00)
Hb-Hb (Hb-SOD-CAT) b     0.33 (0.04)   0.37 (0.03)   0.11 (0.01)
Wavelength (nm)













Hb-Hb (1:10)  Control 
Hb-Hb (1:10)  (0.1mM H202 
Hb-Hb (1:10)  (1mM H202) 
HB-SOD-CAT (1:10)  Control 
HB-SOD-CAT (1:10)  (0.1mM H202) 
HB-SOD-CAT (1:10)  (1mM H202) 
  (3 hours) Absorbance Change at        540nm           575nm           630nm
Hb-Hb (Hb-SOD-CAT) a     0.34 (0.04)   0.40 (0.05)   0.12 (0.01)
Hb-Hb (Hb-SOD-CAT) b     0.39 (0.04)   0.45 (0.05)   0.12 (0.01)
 
Figure 2.5. Protective effect of SOD and CAT on cross-linked Hb (Hb:PEG ratios 
of 1:5 to 1:30 and SOD/CAT enzyme ratio of 30000:300000) challenged with 0.1 
and 1 mM H2O2 for 30min and 3h. Change in absorbance values represents 
difference between free Hb and cross-linked products. Values in parentheses 
refer to conjugates with SOD and CAT: a) refers to conjugates challenged with 


















Hb-Hb (1:10) Control 
Hb-Hb (1:10)  (0.1mM H202) 
Hb-Hb (1:10)  (1mM H202) 
HB-SOD-CAT (1:10) Control 
HB-SOD-CAT (1:10)  (0.1mM H202) 
HB-SOD-CAT (1:10)  (1mM H202) 
  (48 hours) Absorbance Change at        540nm           575nm           630nm
Hb-Hb (Hb-SOD-CAT) a     0.40 (0.08)   0.45 (0.07)   0.12 (0.01)
Hb-Hb (Hb-SOD-CAT) b     0.46 (0.16)   0.50 (0.16)   0.15 (0.01)














Hb-Hb (1:10)  Control 
Hb-Hb (1:10)  (0.1mM H202) 
Hb-Hb (1:10)  (1mM H202) 
HB-SOD-CAT (1:10)  Control 
HB-SOD-CAT (1:10)  (0.1mM H202) 
HB-SOD-CAT (1:10)  (1mM H202) 
  (24 hours) Absorbance Change at        540nm           575nm           630nm
Hb-Hb (Hb-SOD-CAT) a     0.40 (0.08)   0.42 (0.07)   0.12 (0.01)
Hb-Hb (Hb-SOD-CAT) b     0.45 (0.14)   0.47 (0.13)   0.14 (0.01)
 
Figure 2.6. Protective effect of SOD and CAT on cross-linked Hb (Hb:PEG ratios 
of 1:5 to 1:30 and SOD/CAT enzyme ratio of 30000:300000) challenged with 0.1 
and 1mM of H2O2 for 24 and 48h. The change in absorbance value represents 
the difference between free Hb and cross-linked products. Values in parentheses 
refer to conjugates with SOD and CAT: a) refers to conjugates challenged with 




0.50 (48h) units at 575 nm. The results further explain the similar trend of Hb-
only conjugates showing damage/degradation at both concentrations (0.1 and 
1mM) of H2O2 used in the in vitro experiments. The insignificant increase in the 
methemoglobin content peak after 24h in Hb-only formulations may have been 
due to the complete degradation of Hb or further degradation of Hb into ferryl 
Hb or other Hb degradation products (38).  
The changes in the characteristic Hb absorbance peak at 540 and 575 
nm in Hb-only conjugates indicate significant Hb damage and near complete 
degradation of Hb at 48h. The results also indicate that a small quantity of 
peroxide is sufficient to cause Hb damage and render it unsuitable as an O2 
carrier, demonstrating that even though cross-linking may stabilize the 
tetramers of isolated Hb, free radicals can easily damage the unprotected Hb. 
On conjugating Hb with SOD and CAT, the cross-linked formulation 
demonstrated significant Hb-protective effects. The results also show that the 
increase in the absorbance of methemoglobin peaks were less than 0.01 units 
in all cases at 48h of challenge at room temperature, indicating near complete 
Hb protection from H2O2-generated free radicals. The graphical overlay of Hb 
not challenged by H2O2 was very similar to that of Hb conjugates containing 
SOD and CAT that were challenged by H2O2. These results strongly indicate 
that the incorporation of SOD and CAT may provide Hb with enhanced 





2.4.8 Protection of Hb from superoxide  
Challenging (Hb:PEG 1:10 molar ratio) conjugates with xanthine (1 mM) 
and a xanthine oxidase mixture (10 mU/mL and 20 mU/mL) demonstrated 
inhibition of Hb conversion to methemoglobin, with inhibition of decreased Hb 
absorption peaking at 540 and 575 nm, only if SOD and CAT were included in 
the conjugation reaction (Figures 2.7 and 2.8). When Hb-only cross-linked 
conjugates were challenged, a slightly increased absorbance at 630 nm was 
observed and a significant decrease in absorption at 540 and 575 nm, 
indicating a reduction in the Hb content within 30min and a continual decrease 
over a period of 3h. However, Hb conjugates with SOD and CAT demonstrated 
absorption profiles very similar to those of unchallenged conjugates, indicating 
near complete prevention of Hb degradation and inhibition of free-radical 
damage from the superoxide anion for at least 3h (Figure 2.7).  
 Compared to unchallenged Hb, the absorption spectra of the conjugates 
without SOD and CAT after 24 h of superoxide free-radical challenge (Figure 
2.8) show a significant decrease in absorbance at 540 nm (0.10 units with 10 
mU/mL xanthine oxidase and 0.16 units with 20 mU/mL xanthine oxidase) and 
at 575 nm (0.16 units with 10 mU/mL xanthine oxidase and 0.24 units with 20 
mU/mL xanthine oxidase). They also show a significant increase in 
methemoglobin absorbance at 630 nm (0.13 units with 10 mU/mL xanthine 
oxidase and 0.15 units with 20 mU/mL xanthine oxidase) compared to 

















Hb-Hb (1:10) Control 
Hb-Hb (1:10) (XO 10mu/mL) 
Hb-Hb (1:10) (XO 20mu/mL) 
Hb-SOD-CAT Control 
Hb-SOD-CAT (1:10) (XO 10mu/mL) 
Hb-SOD-CAT (1:10) (XO 20mu/mL) 
  (30 mins)
Absorbance Change at        540nm           575nm           630nm
Hb-Hb (Hb-SOD-CAT) a     0.16 (0.01)   0.18 (0.01)   0.02 (0.00)
Hb-Hb (Hb-SOD-CAT) b     0.15 (0.03)   0.18 (0.03)   0.03 (0.00)
Wavelength (nm)













Hb-Hb (1:10) Control 
Hb-Hb (1:10) (XO 10mu/mL) 
Hb-Hb (1:10) (XO 20mu/mL) 
Hb-SOD-CAT (1:10) Control 
Hb-SOD-CAT (1:10) (XO 10mu/mL) 
Hb-SOD-CAT (1:10) (XO 20mu/mL) 
  (3 hours)
Absorbance Change at        540nm           575nm           630nm
Hb-Hb (Hb-SOD-CAT) a     0.17 (0.01)   0.18 (0.03)   0.04 (0.01)
Hb-Hb (Hb-SOD-CAT) b     0.17 (0.04)   0.19 (0.04)   0.04 (0.01)
 
Figure 2. 7. Protective effect of CAT and SOD on cross-linked Hb (Hb:PEG ratios 
of 1:5 to 1:30 and SOD:CAT enzyme ratio of 30000:300000) when challenged 
with 1 mM xanthine and 10 and 20 mUnits/mL xanthine oxidase for 30min and 
3h. Change in absorbance values refers to differences between free Hb and 
cross-linked products. Values in parentheses refer to conjugates with CAT and 
SOD: a) refers to conjugates challenged with 1 mM xanthine and 10 mUnits/mL 
xanthine oxidase and b to conjugates challenged with 1mM xanthine and 20 
mUnits/mL xanthine oxidase. 
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  (24 hrs)













Hb-Hb (1:10) Control 
Hb-Hb (1:10) (XO 10mu/mL) 
Hb-Hb (1:10) (XO 20mu/mL) 
Hb-SOD-CAT (1:10) COntrol 
Hb-SOD-CAT (1:10) (XO 10mu/mL) 
Hb-SOD-CAT (1:10) (XO 20mu/mL) 
Absorbance Change at        540nm	          575nm	          630nm
Hb-Hb (Hb-SOD-CAT) a     0.10 (0.04)	  0.16 (0.06)	  0.13 (0.07)
Hb-Hb (Hb-SOD-CAT) b     0.16 (0.03)	  0.24 (0.05)	  0.15 (0.07)
Wavelength (nm)














Hb-Hb (1:10) Control 
Hb-Hb (1:10) (XO 10mu/mL) 
Hb-Hb (1:10) (XO 20mu/mL) 
Hb-SOD-CAT (1:10) Control 
Hb-SOD-CAT (1:10) (XO 10mu/mL) 
Hb-SOD-CAT (1:10) (XO 20mu/mL) 
Absorbance Change at         540nm	          575nm	          630nm
Hb-Hb (Hb-SOD-CAT) a     0.22 (0.06)	  0.23 (0.08)	  0.15 (0.08)
Hb-Hb (Hb-SOD-CAT) b     0.21 (0.05)	  0.24 (0.07)	  0.20 (0.08)
  (48 hrs)
 
Figure  2.8. Protective effect of CAT and SOD on cross-linked Hb (Hb:PEG ratios 
of 1:5 to 1:30 and SOD:CAT enzyme ratio of 30000:300000) challenged with 1 
mM xanthine and 10 and 20 mUnits/mL xanthine oxidase for 24 and 48h. 
Change in absorbance values refers to differences between free Hb and cross-
linked products. Values in parentheses refer to conjugates with CAT and SOD: a) 
refers to conjugates challenged with 1 mM xanthine and 10 mUnits/mL xanthine 




(from 0 to 0.07 units) in the quantity of methemoglobin in formulations with 
SOD and CAT, the increase was less than that of formulations without SOD 
and CAT (0.07 with and 0.15 units without SOD and CAT), emphasizing the 
importance of antioxidant enzymes in the conjugates. A similar trend is 
revealed in the absorption spectra of the conjugates after 48h, indicating that 
Hb conjugates with antioxidants are afforded better protection than Hb-only 
conjugates at all time periods. Although the results indicate that complete 
protection from the superoxide anion may be achieved by increasing and 
further optimizing the quantity of SOD enzyme in the conjugates, it should be 
noted that Hb was challenged with larger amounts of superoxide anions than 
may be expected in vivo.   
 
 
 2.5 Discussion 
The SDS-PAGE distribution of the Hb-only conjugate clearly shows a 
heterogeneous distribution of conjugates in the cross-linked formulation 
differing little from the Hb polymerized with SOD and CAT. The band 
distributions of SOD and CAT in the gel overlapped with those of Hb, a type of 
SDS-PAGE band pattern often observed and expected in PEG-driven 
chemistries in which chemical modifications are or cannot be tightly controlled 
(39). This type of pattern indicates a high degree of intramolecular cross-linking 
within the Hb molecule to stabilize the tetrameric structure, as well as a high 
degree of intermolecular cross-linking among Hb, SOD, and CAT, resulting in 
an overall increase in the molecular weight of the Hb conjugates. However, the 
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average molecular weight for conjugates of different PEG and Hb ratios only 
slightly differed from those with similar distribution profiles. For Hb-SOD-CAT 
conjugates, the shift in their intensity peak toward lower-molecular-weight 
conjugates or their preference for formation of lower molecular conjugates may 
indicate a decrease in intermolecular cross-linking. Despite changes in their 
elution profiles, as had been expected, it appears that heterogeneous mixtures 
of Hb conjugates are suitable for functions such as encapsulation with isolated 
cells due to their ability to provide O2 to isolated encapsulated cells (13). 
The polymerization method involves conjugation of amine groups on 
amino acid residues, primarily lysine, within the Hb and on the antioxidant 
enzymes (24). A recent study demonstrated that the conjugation of PEG chains 
to Hb lysine residues by thiolation-mediated PEGylation induced structural 
changes by increasing the hydration shell, which assisted in the stabilization of a 
relaxed, high-affinity conformation (40).  The study found that methemoglobin 
levels must be maintained below 10% in PEG-conjugated Hb for the efficient 
oxygenation of tissues (41) and that methemoglobin levels should remain below 
(< 10%) for extended periods following PEG-Hb administration (41).  
Other research has found that human Hb conjugated to maleimide-
activated poly(ethylene glycol) increases in vitro auto-oxidation at room 
temperature and ROS receptivity to enhanced oxidation. Specifically, the rate of 
in vitro heme loss was found to increase fivefold once conjugates were oxidized 
to methemoglobin, which was attributed to the loss of heme in both alpha and 
beta chains (42). PEGylation of Hb at Cys-93 (beta) and Val-1 (beta) was shown 
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to perturb the environment in the heme pocket and increase auto-oxidation, an 
effect shown to be the direct effect of the chemistry of conjugation and not of the 
PEG molecules. However, the PEG chains enhanced auto-oxidation by 
promoting the nucleophilic attack of heme in the presence of H2O2 by increasing 
the quantity of water molecules in the Hb hydration layer (23). Even though the 
exact mechanism by which the quantity of methemoglobin increased in this study 
remains unknown, the results clearly demonstrated that the mechanism that 
increases methemoglobin formation during conjugation is significantly minimized 
or reduced by the addition of antioxidant enzymes, and may therefore be a 
selective chemical or physical Hb modification that provides efficient protection 
against oxidant stress during conjugation and storage at 4 0C. A recent study 
found that Hb-SOD chimeric protein conjugates co-expressed by the human 
alpha and beta Hb chain and manganese SOD gene together in Escherichia coli 
exhibited an auto-oxidation rate 44% lower than that of a control, and were thus 
beneficial (43). 
  In the conjugation method used in this study, PEG was conjugated to 
SOD lysine amino residues, primarily by acylation reaction, to yield amide 
bonding. Due to the large number of amines available on the SOD surface (20 in 
the dimeric enzyme)(44); heterogeneous products are generally obtained due to 
steric hindrance, differences in reactivity, and nucleophilicity. It has been shown 
that the loss of enzymatic activity of PEGylated SOD is related to a decrease in 
the ability to direct the O2-  ion toward the active enzyme site (45). Some loss of 
enzymatic activity in the conjugation performed in this study may have been due 
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to the masking of positive charges by PEG involved in channeling the superoxide 
ion on the active site. It may also have been due to modification of the 
involvement of the positively-charged lysine amino group in the electrostatic loop 
that drives the substrate superoxide anion to the active site. The fact that an 
increasing quantity of PEG in the conjugation reaction did not further decrease 
the enzyme activity, as all 20 lysines in dimeric SOD enzyme are not involved in 
conjugation, may have been due to steric hindrance. The results obtained in this 
study are thus consistent with observations made by Veronese et al. (44), and 
indicate that the level of enzymatic activity depends on the type of conjugating 
agent used. 
Catalase has approximately 112 amino groups (-NH2) available for 
chemical modification by the method of PEG cross-linking used in this study, but 
it is unclear how many are readily accessible for reaction. It was previously 
shown that only about 26 amino residue groups that were modified in a similar 
PEG-modified CAT process retained greater than 90% of their enzymatic activity. 
The slight decrease was attributed to the modification of the tertiary structure in 
the catalytic site by amidination of the amino group (46).  
It has been shown that methemoglobin can be reduced in Hb-loaded 
nanoparticles by prereduction of raw Hb using sodium dithionite post-
encapsulated with SOD and CAT (9). However, long-term stability, enzyme 
leaching, and the presence of Hb in a non-cross-linked or polymerized state may 
become concerns when using this approach. In normal in vivo conditions, Hb is 
present in ferrous form (Fe+2), in which it functions as an effective O2 carrier 
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protected by both an enzymatic and non-enzymatic-rich antioxidant environment. 
Methemoglobin, is converted back to Hb by the methemoglobin reductase 
(metHb) system and maintained in the Fe+2 state at levels above 98%. 
Spontaneous auto-oxidation of Hb causes the production of the superoxide anion 
(O2·-) by removing the electron from the ferrous Hb and converting it into ferric 
(Fe+3) methemoglobin. The superoxide anion causes increased H2O2 production 
by various indirect mechanisms and damage to Hb and its surrounding cellular 
environment (47). Under normal conditions, iron released from Hb or free Hb will 
be removed by complexation with haptoglobin, and thus heme-related toxicity is 
avoided (38). However, in excessively oxidative situations, Hb is converted into 
methemoglobin (Fe+3) and ferryl Hb (Fe+4) and releases globulin and free iron. 
The free iron reacts with H2O2 to produce the hydroxyl radical (OH·) by Haber-
Weiss and Fenton chemistry (47), which further enhances the release of heme, 
which has been shown to cause cellular damage in both humans and animal 
models by different pathways (48). Simoni et al. demonstrated that particularly 
modified Hb solutions increased lipid peroxidation, and thus the cellular damage 
mediated by free-radical processes (49).  
 Recent studies have found that PEG cross-linked Hb-SOD-CAT with an 
Hb/PEG ratio of 1:20 contains less than 2% methemoglobin, in contrast to the 
reported 7% value for the cross-linked product immediately after cross-linking 
with a Hb/glutaraldehye ratio of 1:17. The content of methemoglobin with a 
Hb/glutaraldehye ratio of 1:17 was found to increase by 10% within only 5 days, 
compared to less than 10% for a Hb/PEG ratio of 1:20 within 30 days when 
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incubated at 4 0C (50). These results clearly illustrate one advantage of using 
PEG rather than glutaraldehyde, and it is anticipated that the conjugates will 
perform even better in long-term studies. Another advantage of using PEG-based 
conjugates is greater effectiveness in severely hypoxic and low-pressure 
conditions where the conjugate has a p50 of 7 mm Hg (51), as compared to 
using 25 mm Hg of high-p50 glutaraldehyde (52).  
This study used Hb conjugates with an Hb:PEG ratio of 1:10 to test for the 
existence of a protective effect against free radicals because these conjugations 
had been shown to decrease methemoglobin content during conjugation and 
storage for one month. The results of this study demonstrate that cross-linking 
Hb with antioxidant enzymes clearly minimizes or inhibits Hb oxidation by free 
radicals, and thus Hb conversion to methemoglobin. Cases in which isolated 
cells, such as beta or cardiac cells, must be transplanted or stored require the 
use of Hb conjugates that protect cells against both hypoxic and free-radical 
stressors. Extending the life of an O2-carrying agent with antioxidant enzymes 
may provide protection for a longer duration during isolated cell transplantation 
by reducing intracellular and extracellular oxidative stress. As the peroxide and 
superoxide radicals used in this in vitro study were of concentrations significantly 
greater than those present in inflamed or hypoxic states, it is anticipated that 
these conjugates will demonstrate superior functionality in in vivo situations in 








The goal of this work was to develop Hb conjugates of large molecular 
weight cross-linked with antioxidant enzymes using a biocompatible polymer, in 
this case PEG. The results confirm that the approach used in this study leads to 
the formation of large PEG cross-linked Hb-SOD-CAT conjugates that have the 
capacity to protect Hb from free radicals and prevent its conversion to 
methemoglobin during conjugation and storage. The results thus indicate the 
utility of this approach in the co-encapsulation of conjugates with isolated 
pancreatic beta cells for their long-term protection, and thus the extension of their 
in vivo functionality in the treatment of diabetes, due to the large size of the 
conjugates, which helps prevent leakage of the cross-linked conjugates when co-
encapsulated with isolated cells, and to the ability to supply O2, which is crucial 
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3. EFFECTIVENESS OF HEMOGLOBIN CONJUGATES WITH 
ANTIOXIDANT ENZYMES IN PROTECTION OF  




Reproduced in part with permission from 
Nadithe, V., and Bae, Y. H. (2011) Hemoglobin conjugates with antioxidant 
enzymes (Hb-SOD-CAT) via poly(ethylene glycol) crosslinker for protection of 








This study investigated the effectiveness of using a low-p50 Hb-based O2 
carrier conjugated to antioxidants via a dicarboxymethylated poly(ethylene glycol) 
linker in protecting pancreatic beta cells from severe hypoxia at transplantation 
sites. The effectiveness was determined by calculating O2 dissociation curves, 
Hill plots, Bohr coefficients, and the O2 content of Hb conjugates. The protective 
effect due to incubation of Hb conjugates (Hb/PEG molar ratio 1:10) with 
pancreatic beta cells (RINm5F) against hypoxia (6%, 3%, and 1% O2) was 
evaluated by MTT assay and confocal microscopy. The Hb conjugates with 
antioxidant enzymes were found to offer statistically significant protection (p < 
0.01, increased viability ~80%) from hypoxia compared to control cells in a 1% 
O2 environment. Confocal microscopy confirmed that the low-p50 Hb conjugates 
with antioxidants protected RINm5F cells from hypoxia (Scheme 3.1).   
 
 Scheme 3.1: Graphical Abstract 
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3.2    Introduction  
Pancreatic beta cells are susceptible to damage by ROS under diabetic 
and hypoxic conditions, which can lead to islet dysfunction (1-3). Low O2 
pressure (generally between 40 and 5 mm Hg, corresponding to 0.5 to 6% of O2 
pressure), has been experimentally shown to exist in transplanted rat pancreatic 
islets, irrespective of the transplantation site (liver, kidney, or spleen) (4). The 
high sensitivity of islets to hypoxic stresses during islet isolation, 
culturing/maintenance, and posttransplantation is one of the major obstacles to 
successful islet transplantation (5).  Lack of islet revascularization post-
transplantation has also been shown to cause beta cell death in vivo (6). In one 
study, human islets and a beta cell-line (MIN6) under hypoxia (1% O2) 
demonstrated loss of viability due to necrosis within 24h (7). Under these low-
pO2 conditions, hypoxic cell mitochondria also produce ROS, primarily due to 
altered cellular-redox potential caused by the slowing of respiratory chain 
reactions, which decreases the capacity of cytochrome C to trap O2 (8). In vivo, 
tissues and cells with intact blood vessels sense changes in pO2 through 
different mechanisms, and adapt to altered O2 levels by altering ATP production, 
expressing hypoxia-induced factor (HIF) factor, increasing blood flow, and 
forming new blood vessels (9). Under hypoxic stress, intracellular pH may be 
decreased by the acidic environment (10) and the increased demand for O2. 
Therefore, the design of an O2 carrier that can release greater quantities of O2 




Most approaches used to design Hb-based artificial O2 carriers synthesize 
Hb with properties similar to those of Hb inside RBCs using a typical sigmoidal 
cooperative O2 binding. In perfluorocarbon (PFC)-based O2 delivery systems, 
release of O2 is of a linear rather than sigmoidal nature, in contrast to that of 
natural Hb. Low stability and PFC emulsion toxicity, as well as loose O2 binding 
by van der Waals interactions compared to tight chemical bonding in natural Hb, 
are other significant shortcomings of PFC systems (11). These issues cause 
instantaneous release of O2 by PFCs, and may not provide long-term benefits 
under hypoxia compared to low-p50 (high-affinity) O2 systems (12). 
  To overcome the related problems of hypoxia and hypoxia-induced free-
radical stress and/or environmental radicals, a suitable O2 carrier providing a 
combined protective effect is highly desirable, specifically a multifunctional O2 
carrier of low p50 capable of releasing O2 containing an inbuilt antioxidant 
defense mechanism that protects Hb from hypoxia-induced ROS and protects 
cells from hypoxia. Polymerization and cross-linking offer practical means of 
altering p50, depending on the cross-linking agent, and may be mediated by 
chemistry of the conjugation (13). A typical approach described in the literature 
using glutaraldehyde as a conjugating agent results in high p50, which is more 
relevant to normal conditions than the low p50 conditions encountered at 
transplantation sites (14).  Moreover, glutaraldehyde cross-linking promotes 
vasoconstriction (15) and release of the polymeric linker by degradation, leading 
to cytotoxicity (16).  
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In a previous in vitro investigation of the protective effect of Hb–SOD–CAT 
at room temperature, the authors of this paper found that the antioxidant 
mechanism protected Hb from free radical stresses to a significant extent (17). 
The antioxidant enzyme SOD catalyzes the reduction of superoxide radicals to 
H2O2 and O2 while CAT catalyzes the breakdown of H2O2 to H2O and O2. 
Research has shown that linking these enzymes to Hb by PEG only causes 
minimal loss of enzymatic activity postconjugation, with greater than 70% of SOD 
and 90% of CAT activity maintained (17). These enzymes may also provide a 
protective effect against the free radicals induced during hypoxia, and therefore 
help protect cells or tissues (18). In this study, O2-binding and release capability 
was investigated to gain understanding of the means of tailoring low p50 Hb 
conjugates with antioxidant enzymes for specific tissue-engineering applications, 
such as protecting cells/tissues under hypoxia and/or hypoxia-induced free 
radical stress. To do so, this study examined the ability of these conjugates to 
protect a pancreatic beta cell line (RINm5F) under the hypoxic conditions of 6%, 
3%, and 1% O2 levels. 
  
3.3   Experimental section   
3.3.1 Materials 
Bovine RBC suspension was purchased from Innovative Research (Novi, 
MI IC100-0410). Poly(ethylene glycol) (2 kDa); superoxide dismutase from 
bovine erythrocytes (SOD-S7571); bovine liver catalase (CAT-C40); cell culture 
media RPMI-1640 (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
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(MTT); acridine orange (AO); propidium iodide (PI); potassium tertiary butoxide, 
ethyl bromoacetate, N-hydroxy-succinimide (NHS); and N,N′-
dicyclohexylcarbodiimide (DCC) were purchased from Sigma Chemical Co. (St. 
Louis, USA). Penicillin-streptomycin, fetal bovine serum (FBS), and 
TrypsinEDTA-0.25% solution were purchased from Gibco Co. Dialysis 
membranes were purchased from Spectrum Labs (Rancho Dominguez, CA). 
Amicon™ Ultra-15 Centrifugal Filter Units, 50 and 100 kDa, were purchased from 
Millipore Corporation (Billerica, MA). 
 
3.3.2 Conjugation of Hb with SOD and CAT  
 Hb was isolated from freshly collected bovine RBCs using the same 
procedure as that used in the previous experiment, and its purity verified 
employing SDS-PAGE and quantified employing the Drabkins method  (19). PEG 
(2 kDa) was chemically modified as previously described(19); potassium tertiary 
butoxide and ethyl bromoacetate were used to modify the hydroxyl end groups 
on PEG to ethyl-protected carboxymethylated PEG. Basic hydrolysis of this 
intermediate PEG-compound resulted in a mixture of PEG-carboxylic acids. 
Further purification was performed by ion-exchange chromatography. PEG 
dicarboxylic acid used in conjugations was activated employing NHS and DCC. 
Bovine Hb was conjugated with and without SOD and CAT in various Hb:PEG 
conjugation ratios (1:5, 1:10, 1:15, 1:20, and 1:30), as previously described (17). 
The ratio between SOD and CAT was fixed at 30000 to 300000 enzyme units in 
conjugation reactions with antioxidant enzymes. The conjugation reaction was 
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conducted by stirring for 3h at 4 °C and dialyzing the reaction product for 24h. 
Employing Amicon™ centrifugation filters, the desired concentration (1mM) of the 
conjugates was achieved. A 0.22-μm syringe was used to filter the product, 
which was stored at 4 °C until further use. 
 
3.3.3 Measurement of O2 equilibrium curves  
 
The O2 affinity of Hb-based conjugates was experimentally determined 
using the commercially available HEMOX Analyzer and HEMOX Analytical 
Software (TCS Scientific Corporation, New Hope, PA) (20). The O2 equilibrium 
curve for both the O2-association and dissociation phases was measured using 
dual-wavelength absorbance spectroscopy. A Clark electrode was used to 
directly measure the O2 pressure in the sample cuvette. The OEC was obtained 
by plotting changes in optical absorbance on the X-axis and measuring maximum 
absorbance at 560 nm and 570 nm (the reference) at different pressures on the 
y-axis. For all experiments, 0.25 mM-equivalent Hb solution was placed in a 
cuvette containing the hemox solution, and the temperature of the mixture 
equilibrated to 37 °C by continuous heating and stirring while simultaneously 
being completely oxygenated using ultra-high pure O2. A deoxygenation curve 
was obtained by replacing O2 with ultra-high pure nitrogen gas in conditions in 
which Hb becomes deoxygenated (HbO2 ↔ Hb + O2). An oxygenation curve was 
obtained by replacing nitrogen with O2 after the O2 pressure had almost reached 
zero. All the samples are tested at three different pH values (6.5, 7.4, and 8.0) to 
determine their Bohr coefficients.  
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The OEC was obtained by stepwise curve-fitting analysis using the Adair 
equation, which assumes the sequential binding of O2 to Hb at four available 
binding sites, each having a different equilibrium constant (21). The y values 
were calculated from the estimated Adair constants measured at each pressure 















=   
 
where p is O2 pressure; y is the fractional O2 saturation; and a1, a2, a3, 
and a4 are binding constants. 






 versus log (pO2) values. 
The p50 value (the O2 pressure at which the Hb molecule is 50% saturated) was 
calculated by extrapolating the x-axis value (oxygen partial pressure) to the y-
axis value (Hb saturation). The Hill slope at p50 (n50) was obtained by 
calculating the slope at p50. Bohr coefficients were estimated using the Wyman 
equation (22), 
pH∆
∆ 50P log , which estimates the average number of Bohr protons 






3.3.4 Cell culture and hypoxia experiments 
            To estimate the effectiveness of Hb conjugates as O2 carriers under 
hypoxic conditions (6%, 3%, and 1% O2), RINm5F cells (1 × 105 cells per well) 
were seeded using RPMI media containing 10% FBS and allowed to attach to 
plates by overnight incubation at 37 °C with 5% CO2 and 95% air under 
normoxic conditions (21% O2). After 24h, the medium was changed with fresh 
RPMI media containing Hb formulations with and without SOD and CAT. Based 
on our previous results showing low methemoglobin formation (a poor O2 
carrier), the optimized conjugating ratio was set at 1:10 Hb:PEG (17). The 
following groups were examined for the presence of Hb-conjugate activity: (1) 
cells with an RPMI medium only, (2) cells with an RPMI medium and 0.1 mM of 
unconjugated Hb, (3) cells with an RPMI medium and 0.1 mM of conjugated 
Hb-Hb, and (3) cells with an RPMI medium and 0.1 mM of Hb conjugated with 
antioxidants (Hb-SOD-CAT). Hypoxic conditions (6%, 3%, and 1% O2) were 
achieved using a tri-gas incubator (Thermofisher Scientific Inc., Pittsburgh, PA, 
USA) with continuous injection of an appropriate quantity of ultra-high pure N2 
to reach target O2 levels. At equilibrium, the incubator was saturated with the 
required percentage of O2 (6% or 3% or 1%) and 5% CO2, and then balanced 
with N2. The cells were cultured for 48h in triplicate for each group by placing 








3.3.5   O2 content 
 
The O2 content at any given O2 pressure in the medium was calculated 
 
 using the following equation:  
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where 1.34 mL of O2 is bound by a gram of Hb (Hufner’s number); the 
percentage of HbO2 is equal to the quantity of O2 combined with Hb; pO2 is the 
pressure of dissolved O2 in mm Hg; and 0.03 represents the conversion of 1 mm 
Hg of dissolved O2 to mL/L (23, 24). 
 
3.3.6 MTT assay of cell viability 
Cell viability was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) colorimetric assay. After a defined treatment 
incubation period of 48h, MTT was added to the medium to obtain a final 
concentration of 0.5mg/ml, and then incubated at 37 °C under normoxic 
conditions (21% O2) for 3h to allow for MTT reduction. The medium was 
aspirated and replaced with 1 mL of DMSO (dimethylsulfoxide) and incubated for 
another 15min to solubilize the formazan crystals. Absorbance at 570 nm was 
measured using a microplate reader (SpectraMax\M2; Molecular devices; 
Sunnyvale, CA). The absorbance values of all Hb-incubated samples were 
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normalized with the absorbance values of the cells growing in the medium only. 
The data shown in the MTT assay are relative cell viabilities expressed as means 
± S.D. of three independent experiments.  
 
3.3.7 Confocal microscopy 
Apoptotic and dead cells were visualized using two fluorophores, acridine 
orange (AO) and propidium iodide (PI). The cells were incubated at room 
temperature for 15min and permeabilized with the dyes for detection of cell 
viability. Fluorescent images were obtained using the Fluoview confocal 
microscope (FV300, Olympus IX 81 microscope) by excitation of AO and PI at 
500 and 536 nm, respectively, and emission at 530 and 620 nm, respectively. 
After sequential excitation, the green and red fluorescent images of the same 
cells were recorded and further image analysis performed using Image J 
software (http://rsbweb.nih.gov/ij/). 
 
3.3.8 Statistical analysis 
The statistical significance of the differences between the control group 
and the group of Hb-incubated formulations added to cells in hypoxic conditions 
were analyzed by ANOVA testing to compare group means. Multiple 
comparisons, including differences between polymer conjugation ratios, pH 
effect, and antioxidants, were formed by two-way ANOVA testing followed by 
Holm–Sidak testing. All p < 0.05 values were considered to be statistically 
significant. All the data are presented as means ± S.D. 
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3.4  Results  
3.4.1 O2 affinity of cross-linked Hb conjugates 
The OEC of isolated bovine Hb at 37 ºC at different pH values (8.0, 7.4, 
and 6.5; Figure 3.1) shows the level of O2 bounding. Bovine cell-free Hb has a 
p50 of 24.5 ± 0.6 mm Hg at normal physiological pH (7.4), similar to the value 
of 27.4 mm Hg reported in the literature (25). The corresponding values for pH 
8.0 and 6.5 were 14.05 ± 0.35 and 38.66 ± 0.62 mm Hg, respectively, which is 
statistically significant (p < 0.001). These results demonstrate that the O2 level 
in Hb solution is higher under basic conditions than acidic conditions at any 
given partial pressure. The difference also suggests that if cell-free Hb is placed 
in hypoxic tissues with pressure below 10 mm Hg (26, 27) (approximately 1 to 
2% O2), it will become saturated with up to 30%, 16%, and 10% O2 at pH 8.0, 
7.4, and 6.5, respectively, demonstrating that a greater quantity of O2 is 
released in an acidic pH environment. This result also demonstrates that if pH 
decreases during hypoxia, the O2 carrier may unload more O2 for exchange 
with CO2 to protect cells by decreasing acidity. Figure 3.2 indicates that at pH 
7.4 and 37 ºC, there is a statistically significant (p < 0.001) decrease in p50 
values by PEG-2kDa conjugation between Hb conjugates with and without 
SOD and CAT for all molar ratios compared to p50 of cell-free bovine Hb (the 
control).  
A slight but statistically insignificant decrease in p50 was observed when 
varying the PEG ratio in the conjugates with and without SOD and CAT. It may 
be inferred from the results that increasing the concentration of PEG 2 kDa is 
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Figure 3.1. Fractional O2 saturation curves of isolated free bovine Hb at different 
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Figure 3.2.  O2 affinity of conjugated Hb with (Hb-SOD-CAT) and without (Hb-Hb) 
antioxidant enzymes at 50% of Hb saturation with O2(p50) measured in pH 7.4. 
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not essential in further decreasing p50, and an optimum conjugation molar ratio 
was set. The results also show that the addition of antioxidant enzymes into the 
conjugation mixture did not significantly alter the p50 values. More significantly, 
the use of the conjugation method decreased the p50 values of the conjugates 
to ~7 to 10 mm Hg. The lowered p50 value (increased affinity) of these 
conjugates may increase the capacity of O2 carriers to efficiently release higher 
amounts of O2 under hypoxic conditions as compared to high-p50 cell-free Hb. 
 
3.4.2 Hill coefficient and cooperativity 
 
The Hill coefficient expresses the cooperative nature of Hb-O2 binding. 
According to the theory of O2 binding, the binding of one O2 molecule in the 
heme pocket enhances the binding of subsequent O2 molecules, thus yielding a 
typical sigmoidal O2-binding curve with a positive Hill coefficient (28).  The values 
of the Hill coefficients (Figure 3.3) (n50-slope measured at p50) of isolated bovine 
Hb molecules at 37 ºC are 1.76 ± 0.17, 2.28 ± 0.10, and 1.61 ± 0.22 at pH 7.4, 
8.0, and 6.5, respectively. The positive slope values of these pH conditions show 
that isolated Hb exhibits positive cooperative binding, as there is a direct positive 
correlation between the Hill coefficient and the extent of cooperative binding, with 
Hb molecules typically having a Hill coefficient of approximately 2 (29). The 
experimentally determined n50 values also show that Hb has a stronger 
cooperative effect under basic conditions than acidic conditions, indicating that 






































The log p50 values (Figure 3.4) and their corresponding n50 values in Hb 
conjugate formulations with different PEG-2kDa molar ratios at three different pH 
values at 37 ºC show statistical significance (p < 0.001) when compared to the 
free Hb for all pH conditions. The n50 values range from 1 to 1.5 for all 
conjugates without SOD and CAT. Increasing the quantity of PEG 2 kDa for 
conjugation did not change the n50 value, indicating an insignificant change in the 
cooperative nature of O2 binding among the conjugates. Figure 3.5 shows that 
the n50 values of Hb conjugated with SOD and CAT follow a trend similar to that 
of Hb conjugates without SOD and CAT. This finding implies that the addition of 
SOD and CAT does not have a significant effect on the cooperative nature of the 
O2 binding of Hb within the conjugates. Therefore, it may be feasible to adjust the 
quantity of the antioxidant enzymes in the conjugates if a greater antioxidant 
effect is needed. The results show that the conjugation process did not 
significantly change the degree of positive cooperativity in the conjugated Hb, 
both with and without antioxidants. However, the positive cooperativity of Hb in 
Hb-Hb and Hb-SOD-CAT conjugates decreased significantly (p < 0.001) 
compared to that of free Hb. This decrease is also reflected in the altered p50 
values in all the conjugates; at any given molar ratio, a very insignificant change 
in the cooperativity (n50) in different pH conditions can be observed. However, 
increasing the molar ratio of PEG-2kDa led to only an insignificant decrease in 
the Hill coefficients, suggesting that the change in cooperativity with increased 
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Figure 3.4. Hill coefficients (n50) at corresponding log p50 of conjugated bovine 
Hb (Hb-Hb) for different Hb:PEG molar ratios (1:5, 1:10, 1:15, 1:20, 1:30) in 
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Figure 3.5. Hill coefficients (n50) at corresponding log P50 of conjugated bovine 
Hb with antioxidant enzymes (Hb-SOD-CAT) for different Hb:PEG molar ratios 
(1:5, 1:10, 1:15, 1:20, 1:30) in different pH (8.0, 7.4, 6.5) conditions. 
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log p50 and the corresponding n50 value with pH change indicates that the 
conjugates may be less flexible in O2 binding and release than is cell-free Hb. 
  
3.4.3 Bohr effect 
The Bohr effect is the impact of a change in pH on the O2 affinity of a 
saturated oxyhemoglobin molecule. The effect originates from the 
conformational change in tetrameric Hb between the R (oxy) and T (deoxy) 
structure caused by the differences in binding and exchange between O2 and 
H+/CO2 at the binding sites when there are changes in pH. The effect also 
leads to a change in the Hb molecular environment of Bohr groups (specific 
amino acid residues). The binding of O2 to the heme groups decreases the pKa 
of the Bohr groups and makes Hb more acidic, leading to the release of protons 
(30).   
The Bohr effect is measured by the Bohr coefficient, which increases in 
tandem with increases in the quantity of O2 that is off-loaded when a change in 
pH leads to a shift from an alkaline to an acidic condition (31).  Isolated bovine 
Hb was found to have a negative Bohr coefficient of 0.30 (Figure 3.6) within the 
pH range (6.5 to 8.0) tested in this study, which is similar to the values reported 
in the literature (30). Conjugation with PEG decreased the absolute value of the 
Bohr coefficient by at least 50%, a statistically significant (p < 0.001) decrease 
compared to unconjugated free Hb that may have been due to alteration in 
Bohr groups in the Hb. Changing the quantity of PEG used in the cross-linking 




Conjugated bovine Hb's 
















            Hb - Hb
Hb - SOD - CAT
 
 
Figure 3.6. Bohr plot of conjugated bovine Hb with (Hb-SOD-CAT) and without 
(Hb-Hb) SOD and CAT at different Hb:PEG molar ratios (1:5, 1:10, 1:15, 1:20, 
1:30). 
 
The Bohr coefficients for cross-linked Hb indicate only a small change in 
O2 off-loading with a change in pH from 6.5 to 8, demonstrating that cross-
linked Hb are more susceptible to changes in O2 pressure than a pH change 
from an alkaline to an acidic environment. The addition of SOD and CAT did 




3.4.4   O2 content 
          The results displayed in Table 3.1 show that the total available O2 is 
greater when p50 of Hb is lowered and calculated at different hypoxic conditions 
(6%, 3%, and 1%). At 40, 20, and 7 mm Hg of O2 pressure, 1.2, 0.6, and 0.3 
mL/L of soluble O2, respectively, are available in the media for cellular 
respiration, values that are considerably low when compared to a normal O2 
value of 100 mm Hg (3 mL/L). Adding free Hb molecules (0.1mM, p50 ~24.5 mm 
Hg) to the media increases O2 availability by 6.7 ± 0.2, 7.9 ± 0.2, and 1.8 ± 0.1 
mL/L at 40, 20, and 7 mm Hg of O2 pressure, respectively, while adding cross-
linked Hb with and without SOD and CAT increases O2 availability by 7.9 ± 0.2, 
6.8 ± 0.3, and 5.2 ± 0.3 mL/L at 40, 20, and 7 mm Hg, respectively. These results 
show that by lowering the p50 of Hb, the percentage of O2 will likely be increased 
by 18%, 79%, or 189% under a 6%, 3%, and 1% hypoxic condition, respectively, 
demonstrating the importance and usefulness of the low p50 conjugate.  
 
3.4.5   Viability 
MTT assays estimate cell viability by measuring the functional state of the 
mitochondria in cells. Viable cells with active mitochondria convert MTT to 
purple crystals (formazan) that can be dissolved in organic solvents and 
estimated spectrophotometrically. The data (Figure 3.7 and 3.8) demonstrate 
that cross-linked Hb-SOD-CAT (Hb/PEG 1:10 ratio) offers better cell protection 




Table 3.1: Calculated O2 content in Hb formulations (free Hb; conjugated Hb-Hb; 
conjugated with antioxidant enzymes Hb-SOD-CAT) and in media at different 

























6 % ~ 40 
mm Hg 
Hb 6.7 ± 0.2 * 1.2 7.9 
Hb-Hb 7.9 ± 0.1 18 % 1.2 9.1 
Hb-SOD-
CAT 
7.9 ± 0.2 18 % 1.2 9.1 
3 % ~ 20 
mm Hg 
Hb 3.8 ± 0.1 * 0.6 4.4 
Hb-Hb 6.8 ± 0.3 79 % 0.6 7.4 
Hb-SOD-
CAT 
6.8 ± 0.2 79 % 0.6 7.4 
1 % ~ 7 
mm Hg 
 
Hb 1.8 ± 0.1 * 0.21 2.0 
Hb-Hb 5.2 ± 0.2 189 % 0.21 5.4 
Hb-SOD-
CAT 










*Protective effect of Hb-SOD-CAT in hypoxic conditions
RINm5F cells incubated at 37 0C for 48h
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Figure 3.7. Percentage relative cell viability (MTT) of RINm5F cells incubated 
with RPMI media alone, free Hb, and conjugated bovine Hb with (Hb-SOD-CAT) 
and without (Hb-Hb) antioxidant enzymes (Hb:PEG 1:10) for 48h under hypoxic 
conditions (6%, 3%, and 1% O2) (values = mean ± SD; n=3 * p<0.01). MTT 
values were normalized by the respective control cells in RPMI media under 










Protective effect of Hb-SOD-CAT in hypoxic conditions
RINm5F cells incubated at 37 0C for 48h
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Figure 3.8. Percentage relative cell viability (MTT) of RINm5F cells incubated 
with RPMI media alone, free Hb, and conjugated bovine Hb with (Hb-SOD-CAT) 
and without (Hb-Hb) antioxidant enzymes (Hb:PEG 1:10) for 48h under normoxic 
conditions (21% O2) and hypoxic conditions (6%, 3%, and 1% O2) (values = 
mean ± SD; n=3). MTT values were normalized by control cells in RPMI media 







under hypoxic conditions (6%, 3%, and 1% O2) for 48h than do Hb conjugates 
without antioxidant enzymes.  
The percentages of relative cell viability (Figure 3.7) under each hypoxic 
condition (6%, 3%, and 1% O2) were calculated by normalizing MTT 
absorbance values with control cells growing in RPMI media alone. The use of 
cell-free Hb (p50 value of 24.5 mm Hg) demonstrated only a 5% to 10% higher 
cell viability compared to cells growing under hypoxic conditions, suggesting 
that it has a poor protective effect. The use of cross-linked Hb (Hb-Hb) (p50 
value ~8 mm Hg) increased the viability by 5 ± 17%, 15 ± 9%, and 30 ± 13% 
under a 6%, 3%, and 1% hypoxic condition, respectively. When Hb was cross-
linked with antioxidant enzymes with a similar p50 value of 8 mm Hg, the cell 
viability was further increased by 32 ± 10%, 52 ± 12%, and 81 ± 13% under a 
6%, 3%, and 1% hypoxic condition, respectively. Statistical analysis 
demonstrated that the use of Hb with antioxidants provided a level of protection 
to RINm5F cells that was statistically greater than that provided by control cells 
with media alone (p < 0.01), free Hb (p < 0.01), and cross-linked Hb-Hb (p < 
0.05). The use of cross-linked Hb with antioxidants appears more effective in 
1% O2 which is relevant to islet transplantation. 
When the absorbance values were normalized by control cells under 
normoxic conditions (21% O2) (Figure 3.8), the viability of cells growing in 
RPMI media alone under hypoxic conditions (6%, 3%, and 1% O2) decreased 
by 63 ± 11%, 50 ± 3%, and 45 ± 2% under a 6%, 3%, and 1% hypoxic 
condition, respectively. The use of cell-free Hb (p50 value 24.5 mm Hg) 
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decreased viability by 66 ± 17%, 57 ± 9%, and 59 ± 13% under a 6%, 3%, and 
1% hypoxic condition, respectively. The use of cross-linked Hb (p50 value ~8 
mm Hg) decreased viability by 83 ± 10%, 75 ± 12%, and 82 ± 13% under a 6%, 
3%, and 1% hypoxic condition, respectively. 
  
3.4.6 Confocal microscopy 
A combination of acridine orange (AO), a cell-permeable fluorescent dye 
that binds to DNA and emits green light when incorporated into normal healthy 
living cells, and propidium iodide (PI), a dye that emits red light when 
incorporated into the DNA of apoptotic or dead cells, to which it is permeable 
due to damage to the cell membrane, is used to qualitatively distinguish 
apoptotic from viable cells. Figures 3.9, 3.10, and 3.11 shows the confocal 
images of the RINm5F cells incubated with free Hb and Hb conjugates for 48h 
under hypoxic conditions. Control cells growing in 6%, 3%, and 1% O2 
demonstrated extensive cell membrane destabilization, leading to their uptake 
of PI. The decreased uptake of AO and the increased uptake of PI were greater 
in the control cells growing in 1% O2, indicating the decreased viability of 
normal cells under harsh hypoxic conditions and the rapid death of cells 
incubated under hypoxic conditions without free and cross-linked Hb. The cells 
incubated in 6% O2 with free and conjugated Hb demonstrated slightly higher 
cell viability (as observed in the MTT assay) compared to control cells, but no 
significant qualitative differences were found between the AO and PI uptake of 






Figure 3.9.  Confocal laser scanning microscopy images of RINm5F cells 
incubated with A) media only B) free Hb C) cross-linked Hb-Hb (Hb/PEG 1:10) 
and D) cross-linked Hb-SOD-CAT (Hb/PEG 1:10) for 48h under hypoxic 





Figure 3.10. Confocal laser scanning microscopy images of RINm5F cells 
incubated with A) media only B) free Hb C) cross-linked Hb-Hb (Hb/PEG 1:10) 
and D) cross-linked Hb-SOD-CAT (Hb/PEG 1:10) for 48h under hypoxic 





Figure 3.11. Confocal laser scanning microscopy images of RINm5F cells 
incubated with A) media only B) free Hb C) cross-linked Hb-Hb (Hb/PEG 1:10) 
and D) cross-linked Hb-SOD-CAT (Hb/PEG 1:10) for 48h under hypoxic 




However, the cells incubated in 3% O2 with free Hb or conjugated Hb without 
SOD and CAT demonstrated significant PI uptake, indicating cell death.  
The cells incubated with Hb conjugated with SOD and CAT 
demonstrated much higher viability. The cells growing in 1% O2 and incubated 
with Hb-SOD-CAT were very permeable to AO, indicating a dramatic reduction 
in apoptosis. The results clearly demonstrate that Hb was effective in supplying 
O2 from the conjugated Hb in severely hypoxic environments. More 
significantly, they suggest that low-p50 cross-linked Hb with antioxidants offers 




The extent to which the efficiency of isolated Hb-based O2 carriers can 
be improved depends primarily on the manner in which Hb is modified. When 
designing low-p50 O2 carriers, the type of conjugating agent and the 
conjugation chemistry must be carefully considered, as they may significantly 
alter the sigmoidal shape of modified Hb, leading the shape of the resulting 
curve to differ from that of the typical OEC. This study found that employing 
glutaraldehyde, a commonly employed cross-linking agent that has been 
extensively reported in the literature, resulted in high p50 poly-Hb in 20:1 
glutaraldehyde-Hb conjugation reactions. Although increasing the 
glutaraldehyde ratio to 40:1 decreased the p50 to 13 mm Hg, it also resulted in 
a significant conversion of Hb into methemoglobin (30%), potentially reducing 
 
116 
the role of the glutaraldehyde-Hb conjugation as an efficient O2 carrier (32) 
under hypoxic conditions.  
This study found that PEG-driven cross-linking significantly changed the 
shape of the OEC, and thus the quantity of O2 released at different O2 
pressures, Hill coefficients, and Bohr coefficients. The O2 carriers created by 
the PEG-conjugation chemistry used in this study decreased the p50 to ~8 mm 
Hg at a 10:1 PEG/Hb ratio and produced a minimal quantity of methemoglobin  
( < 5%)(17), suggesting that these O2 carriers may function efficiently during 
islet-cell transplantation, especially under severe hypoxic conditions. A recent 
study found that the conjugation of PEG chains to Hb lysine residues by 
thiolation-mediated PEGylation induced structural changes by increasing the 
hydration shell, which further assisted in the stabilization of Hb into a desirable 
relaxed state (33). This stabilization into a relaxed state by increasing the PEG 
hydration shell or other modifications that aid in the transition of Hb from T to R 
conformation may be responsible for decreasing the p50 (13). However, using 
the current method of conjugation, it is not feasible to determine which amino 
group perturbation(s) is/are critical for decreasing the p50 of Hb molecules, and 
thus decreasing the p50 of the final conjugates (34). 
Interestingly, this study found that increasing the concentration of PEG 
did not significantly decrease the p50, contrary to initial assumptions based on 
the literature (32). One explanation may be that amino groups (34) involved in 
the structural changes in the OEC at Hb:PEG molar ratios below 1:15 undergo 
complete modification. This study found only an insignificant change in the Bohr 
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coefficient of Hb, as well as that the addition of antioxidant enzymes did not 
significantly change the p50 of cross-linked Hb. The finding that there were no 
significant changes in O2 release after pH changes in the tissue or cellular 
environment indicates that O2 release by conjugated Hb is more susceptible to 
hypoxic conditions (O2 levels less than 6%) than changes in cellular or media 
pH. The alterations in cooperativity and the Bohr coefficient that were observed, 
which are similar to those observed using most polymerization techniques (35, 
36), may be attributed to the transformation of Glu-101 beta into acidic Bohr 
group which is in close proximity to Lys-99 alpha in oxyhemoglobin that may be 
involved in cross-linking (37).  
For p50 of 24.5 mm Hg and n = 1.75, free Hb saturation was found to vary 
from 10% to 70% when the pO2 changed from 7 to 40 mm Hg (~1 to 6% O2). 
The saturation for cross-linked Hb-Hb or Hb-SOD-CAT was found to vary from 50 
to 90% for p50 of 8 mm Hg and n = 1.2, indicating that cross-linking can 
effectively buffer Hb for cell transplantation under hypoxic conditions of 1 to 6% 
O2. In the Hb in human RBCs, the T state (low O2 affinity, high p50) is stabilized 
when 2,3 - BPG binds to deoxyhemoglobin by forming salt bridges with lysine 
and histidine residues (38). This causes the release of O2 to surrounding tissues 
rather than its binding to Hb in the presence of 2,3-BPG and assists in 
oxygenation during tissue hypoxia.  
It is important to note that bovine Hb, which was used in this study, does 
not behave in the same manner as 2,3-BPG allosterically, nor does myoglobin, 
as 2,3-BPG and has no effect on it (39, 40). It has been shown that the high O2 
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affinity (low p50) and reduced cooperativity of PEG-modified Hb could lead to 
modification of four alpha-amino groups on Hb, as well as that the impact of 
lengthy PEG chains could lead to modification of the amino termini. Modification 
of val-1(α) only or of both Val-1(α) and Val-1(β) has also been shown to increase 
the O2 affinity (low p50) of Hb. The stabilization of a high O2 affinity has been 
explained as the impact of PEG on the Hb hydration shell. The epsilon-amino 
group of Lys-40(α), which forms a salt bridge with the alpha-carboxyl of His-
146(β), may have played an important role in the cooperative O2 binding by Hb 
observed in this study (41). However, the exact cause of the change in O2 affinity 
due to the method used in this study cannot be determined at this stage. 
Among the different conjugates that have been used in experiments 
under hypoxic conditions, this study used conjugates with a 1:10 (Hb:PEG) 
ratio in its MTT viability investigation. Molar ratios higher than 1:10 provide no 
additional benefit in terms of O2 equilibrium properties, such as a low p50 
value. The benefits of employing low-p50 systems in this study were similar to 
results observed by Sakai et al. when being compared to high-p50 systems 
(42). Although the O2 content in low-p50 Hb conjugates with and without 
antioxidants was found to be similar under hypoxic conditions, the MTT results 
indicate greater cell viability in Hb conjugates with antioxidants. It was 
previously found that PEG-conjugated Hb (MP4) incubated at 37 ºC for 18h 
produced 30 to 40% methemoglobin as the Hb underwent auto-oxidation (43). 
Based on previous research, this finding may be attributed to the protection of 
Hb by antioxidant enzymes in hypoxic environments from hypoxia-induced free-
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radical stress and/or auto-oxidation, and thus greater cell viability, as indicated 
by the greater quantity of O2 released in this study. As the conversion of Hb to 
methemoglobin is not instantaneous, the low-p50 Hb conjugate demonstrated 
greater cell viability than the free-Hb conjugate under severe hypoxic conditions 
(1% O2). Despite the fact that the qualitative confocal images were similar for 
Hb conjugates with and without antioxidant enzymes, the differences in their 
cell viability may be the reason why RINm5F cells under normoxia multiply in a 
different manner from RINm5F cells under hypoxia (44).  
The cells of cross-linked Hb in this study demonstrated 10 to 80% 
greater cell viability, depending on the severity of hypoxia, than did cells without 
any added Hb. The confocal microscopy results support the findings of the MTT 
assay. The significantly greater uptake of PI by the control RINm5F cells than 
of cells incubated with conjugated Hb clearly demonstrates the effectiveness of 
using conjugated Hb for O2 transport under hypoxic conditions. Conjugated Hb 
may also be used for enhancing the survival of different cell or tissue types for 
temporary storage after isolation or during transplantation of beta or cardiac 
cells, as well as when treating ischemic conditions or related complications (45-
47). For isolated beta-cell transplantation in low O2 sites, such as the peritoneal 
cavity, exogenous low-p50 Hb conjugated with antioxidants may help prevent 
O2 transport issues and reduce cell death from hypoxic and free-radical 
stresses. Due to the capacity of conjugated Hb to unload a greater quantity of 
O2 into the cellular environment more efficiently under hypoxic conditions, and 
thus improve overall metabolic function, using conjugated Hb with low p50 in 
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such situations may be more beneficial than using high-p50 systems or other 
O2 carriers (48-52). 
 
3.6 Conclusion 
The experiments performed in study demonstrated that the use of PEG-
conjugated Hb with antioxidant enzymes can protect cells from hypoxia, a 
unique feature of low-p50 systems. The results reported here thus provide 
useful data for the optimization of O2 carriers intended for therapeutic or 
prophylactic purposes under hypoxic and ischemic conditions. This study also 
described the design and use of a general approach for protecting isolated cells 
and tissues from combined hypoxia-induced oxidative and hypoxic stress. 
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4.1 Abstract  
Cross-linked hemoglobins using dicarboxymethylated poly(ethylene 
glycol) with the antioxidant enzymes superoxide dismutase (SOD) and catalase 
(CAT) were designed for the protection of pancreatic beta-cells from combined 
free-radical and hypoxic (6% and 1% oxygen) stress in conditions similar to islet 
transplantation. 
In this study, the RINm5F (cell line) and isolated pancreatic beta-cells with 
oxidants (1mM H2O2 or 1mM xanthine and 10mU/mL xanthine oxidase) were 
challenged and incubated with hemoglobin conjugates (0.1mM Hb-Hb or Hb-
SOD-CAT) in normoxia (21%) and hypoxia (6 and 1%) oxygen. Absorption 
spectroscopy and methemoglobin assay were used to evaluate hemoglobin 
protection at 37 °C for 24h. Intracellular free radical activity and cell viability in 
RINm5F cells were measured by DCFDA and MTT assay. Radioimmunoassay 
was used to quantify insulin release in isolated islets. Confocal microscopy was 
used to qualitatively evaluate cell viability. 
Results show that Hb-SOD-CAT helped maintain glucose-induced insulin 
secretion in beta-cells and RINm5F cell viability from combined oxidative and 
hypoxic stress. The study also suggests that antioxidant enzymes will play a 
significant role in the protection of hemoglobin in the conjugate and thus the 
extended cell protection in free radical and hypoxia-induced stress. These results 
also show the potential of Hb-SOD-CAT to prevent beta-cell dysfunction 
associated with free-radical and hypoxic stress in transplantation conditions. 
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4.2 Introduction 
Islet transplantation can circumvent the need for daily injections of 
exogenous insulin in patients with Type 1 insulin-dependent diabetes mellitus (1). 
Even though this approach has shown some success, its widespread use is 
limited by islet donor shortage and long-term islet viability (2). Cell encapsulation 
and the use of nonhuman islets for transplantation can solve the problems of 
human islets scarcity and the need for immune suppression (3). Unfortunately, 
the long-term viability of isolated devascularized islets following transplantation 
remains an issue for achieving successful, long-term normoglycemia (4). Factors 
such as islet damage by reactive oxygen species sustained immediately after 
islet isolation from the pancreas or during ex vivo cell culture (5), hypoxia (6), 
hypoxia-induced free-radical damage  (7), and low partial oxygen pressures at 
the transplantation sites (8) are other important factors contributing to the loss of 
beta-cell viability and further hindering successful encapsulated islet 
transplantation. The presence of low levels of anti-oxidative enzymes and the 
minimal antioxidant capability of beta cells necessitate an antioxidant defense 
mechanism (9) to protect isolated islet beta cells. 
A protective agent(s)/system that can be transplanted along with the islets 
at the transplantation site is necessary if the combined problem of hypoxia and 
free-radical stress on beta cells is to be overcome. Literature and previous 
results (10, 11) have shown that PEG-stabilized hemoglobin is a successful 
artificial oxygen carrier that can help in supplying oxygen to isolated cells. 
However, the long-term use of these cross-linked hemoglobins when co-
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encapsulated with islets is limited by the continuous conversion of hemoglobin to 
methemoglobin by auto-oxidation (12, 13) and free radical damage (14). To 
overcome the problem of free radical damage to hemoglobin, modified 
dicarboxymethylated (PEG) was synthesized and used it to link two antioxidant 
enzymes, superoxide dismutase (SOD) and catalase (CAT), to hemoglobin, 
creating hemoglobin (Hb) conjugate system. Previous in vitro studies using the 
conjugate system (Hb-SOD-CAT) had shown that the hemoglobin was protected 
effectively from free-radical damage caused by the superoxide anion and from 
hydrogen peroxide damage at room temperature (15) . PEG as the conjugating 
agent aided in designing a low p50 hemoglobin oxygen carrier that could unload 
higher amounts of oxygen when exposed to low partial oxygen pressures or 
under hypoxic conditions. This design also helped protect isolated cells in severe 
hypoxic stress when conjugated with SOD and CAT (16).  
In this research, the robustness of the hemoglobin conjugated with a SOD 
and CAT system in a hypoxic (6% or 1% oxygen) and free-radical-rich 
environment were further tested to determine its suitability for long-term 
protection at transplantation sites. The effectiveness of SOD and CAT in 
protecting oxygen-loaded hemoglobin was tested in normoxia (21%) and hypoxia 
(6% or 1%) using cell incubation conditions that were relevant to an in vivo 
transplantation environment. After being challenged with superoxide anions, the 
hydroxyl ion and free radicals generated by hydrogen peroxide overall cell 
viability, intracellular free radical activity of a pancreatic beta cell line (RINm5F) 
was evaluated. Insulin-secreting capability by the primary isolated pancreatic 
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beta-islets was also determined. Cells were incubated at normal (21%) or 
hypoxic (6% or 1%) oxygen levels for 24h at 37 °C. Confocal microscopy was 
used to visually examine and corroborate the effectiveness of the Hb-SOD-CAT 
conjugate in preserving RINm5F cells and isolated islet viability when subjected 
to both hypoxic and free radical stresses. 
 
4.3 Experimental section 
4.3.1 Material 
Freshly pooled bovine red blood cell suspension was purchased from 
Innovative Research (Novi, MI IC100-0410). PEG (2 kDa), potassium tertiary 
butoxide, ethyl bromoacetate, N-hydroxysuccinimide (NHS), N,N′-
dicyclohexylcarbodiimide (DCC), superoxide dismutase from bovine erythrocytes 
(SOD-S7571), bovine liver catalase (CAT-C40), hydrogen peroxide (H2O2), 
xanthine, xanthine oxidase (XO), acridine orange (AO), propidium iodide (PI), (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)), RPMI 1640 
culture medium powder, bovine serum albumin (BSA), and Dulbecco’s 
phosphate buffered saline (DPBS) were purchased from Sigma Chemical Co. 
(St. Louis, MO). Penicillin-streptomycin, fetal bovine serum (FBS), trypsin/EDTA-
0.25% solution and 2′, 7′-dichlorodihydrofluorescein diacetate (H2DCF-DA) were 
purchased from Invitrogen, Inc. (Carlsbad, CA). Dialysis membranes were 
purchased from Spectrum Labs (Rancho Dominguez, CA). Amicon Ultra™-15 
centrifugal filter units (50 and 100 kDa) were purchase from Millipore Corporation 
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(Billerica, MA). A 125I-Insulin radioimmunoassay (RIA) kit was purchased from MP 
Biomedicals, Inc. (Irvine, CA). 
 
4.3.2 Conjugation of Hb with SOD and CAT  
As described previously (11), the hydroxyl end groups on PEG (2 kDa) 
were chemically modified to ethyl-protected carboxymethylated PEG using 
potassium tertiary butoxide and ethyl bromoacetate. Basic hydrolysis of ethyl-
protected carboxymethylated PEG resulted in a mixture of PEG mono- and 
dicarboxylic acids. Purified PEG dicarboxylic acid was obtained by ion-exchange 
chromatography. NHS and DCC were used to further activate the purified PEG 
dicarboxylic acid. The activated PEG, PEG-NHS (from diacid) was characterized 
by 1H NMR spectroscopy and thin-layer chromatography prior to use in the 
conjugation reaction. Fresh hemoglobin was isolated from bovine red blood cells 
using previously described methods (11, 15) . The hemoglobin was quantified 
using Drabkin’s method, and the purity was confirmed by SDS-PAGE (11). For 
the conjugate formulation containing hemoglobin only (Hb-Hb), isolated purified 
hemoglobin was cross-linked using activated PEG at a fixed weight ratio of 
Hb:PEG (1:10). For the conjugate formulation containing antioxidant enzymes, 
the two antioxidant enzymes (SOD and CAT) at a fixed ratio of 150000 to 300000 
enzyme units were mixed with hemoglobin using the same conjugation ratio of 
Hb:PEG (1:10), as described previously (15). The reaction was carried out at 4 
°C for 3h with constant stirring, and the product was further dialyzed against PBS 
for 24h using dialysis membranes (MWCO 100 kDa). The desired concentration 
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of the conjugates (0.1mM) was achieved by concentrating the formulation using 
Amicon™ ultracentrifugation filters. The product was filter-sterilized using a 0.22 
μm syringe filter and stored at 4 °C until further use. 
 
4.3.3 Absorption spectrum of the conjugated hemoglobins after being  
challenged with free radicals (peroxide and superoxide) 
in normoxia and hypoxia at 37 °C 
To study the protective effect of the antioxidant enzymes on hemoglobin in 
the combination formulation (Hb-SOD-CAT) in a hypoxic environment at 37 °C, 
the Hb-Hb and Hb-SOD-CAT (Hb:PEG 1:10) conjugates (each containing the 
equivalent of 0.1mM hemoglobin) were tested by exposing conjugated 
formulations to superoxide anion generated by 1mM xanthine and 10 mU/mL 
xanthine oxidase and hydroxyl free radicals generated by 1mM hydrogen 
peroxide in 24-well plates and incubated for 24h. The qualitative analysis of free 
radical and hypoxia-challenged conjugated hemoglobin systems was evaluated 
by measuring the visible absorption spectrum of conjugated hemoglobins using a 
UV-visible spectrophotometer (SpectraMax, Molecular Devices; Sunnyvale, CA). 
At the end of the 24h period, the conjugates were scanned through the visible 
absorption spectrum from 450 nm to 750 nm at a rate of 2 seconds. 
 
4.3.4 Methemoglobin quantification 
 The methemoglobin content in the conjugated samples that had been 
challenged with free radical and hypoxic stress for 24h was determined using 
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methods previously described (17) and summarized as follows: Sufficient 
amounts of the challenged conjugates were transferred into a UV-visible cuvette 
by diluting the sample such that the absorbance reading (A1) at 630 nm was less 
than one unit. The sample was allowed to react with 50 μL of potassium cyanide 
solution (1 part 10% KCN and 1 part PBS pH 7.5). After the samples were 
reacted for 5-10min, a second absorbance measurement (A2) was taken at 630 
nm. The methemoglobin content was calculated using the equation below:  
 
  factor dilution  
3.7
A2-A1   binMethemoglo ×=  
 
wherein the two absorbance values (A1 and A2) were subtracted from each other 
and divided by the extinction coefficient value (3.7 cm mM-1). To determine the 
total hemoglobin content in the challenged conjugated samples, 50 μL of 20% 
K3Fe(CN)6 was added to the sample to convert any remaining oxy- and deoxy- 
hemoglobin species to methemoglobin. After another 50 μL of 10% KCN was 
added, a third absorbance peak (A3) was measured at 540 nm. The hemoglobin 
content was calculated by dividing the A3 absorbance value by the 
cyanomethemoglobin extinction coefficient of 11 cm mM-1 and multiplying by the 
dilution factor. The percentage of methemoglobin in the sample was calculated 
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  factor dilution  
11
A3   Hemoglobin ×=  
 
4.3.5 Hypoxic and oxidative stress 
Hypoxic stress was induced using a tri-gas incubator (Thermofisher 
Scientific Inc., Pittsburgh, PA) with continuous flushing of ultra-high pure N2 to 
obtain the target hypoxic oxygen levels (6% or 1% of O2). At equilibrium, the 
incubator contained either 6% or 1% of O2, 5% CO2 and rest balanced with N2. 
Normoxic conditions (21% O2) were maintained using a mixture of 95% air and 
5% CO2.  
Oxidative stress was induced either by superoxide anion generated by 
1mM xanthine and 10 mU/mL xanthine oxidase system (18) , or by hydroxyl free 
radicals by using 1mM hydrogen peroxide (19) . For all oxidant-challenge cell 
experiments, RIN5mF cells or islets were cultured in the presence of oxidants for 
24h in the incubator at 37 °C with n = 3.  
 
4.3.6 Experimental groups 
Experimental groups consisted of optimized hemoglobin conjugates made 
using the conjugation ratio of 1:10 Hb:PEG. This ratio was chosen from the 
previous optimized formulation that had low methemoglobin formation (15) and 
was an efficient oxygen carrier in hypoxic conditions (16). The following groups 
were selected for demonstrating the protective activity of Hb-conjugates: (1) cells 
with medium only; (2) cells with medium containing 1mM H2O2 or 1mM xanthine 
and 10mU/mL xanthine oxidase; (3) cells with medium containing 0.1mM 
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conjugated Hb-Hb and 1mM H2O2 or 1mM xanthine and 10mU/mL xanthine 
oxidase; (4) cells with medium containing 0.1mM hemoglobin conjugated with 
antioxidants (Hb-SOD-CAT) and 1mM H2O2 or 1mM xanthine and 10mU/mL 
xanthine oxidase.  
 
4.3.7 Cell culture (pancreatic islets and RINm5F cell line) 
Pancreatic islets were either isolated from male Sprague-Dawley Rat 
(200-250 grams) using enzymatic collagenase digestion and discontinuous Ficoll 
density gradient separation techniques (10, 11) or purchased from Joslin 
Diabetes Center, Boston, MA. Upon isolation or receipt, islets were cultured in 
RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin 
in a cell culture incubator maintained at 37 °C containing 95% air / 5% CO2 at 
normal humidity. Isolated islets were cultured for 24 to 48h before use in 
experiments. The normalized islet equivalent (islet size of 100 µm) was used to 
account for the natural variability in islet size.  
RINm5F cells (rat insulinoma cell line) were cultured in RPMI1640 medium 
supplemented with 10% FBS and 1% penicillin/streptomycin in a cell culture 
incubator maintained at 37 °C containing 95% air / 5% CO2 at normal humidity. 
Cells were harvested using 0.25% trypsin/10 mM EDTA. RINm5F cells were 
seeded (1 × 105 cells per well) in tissue culture plates and allowed to attach for 
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4.3.8 Measuring intracellular reactive oxygen species (ROS) levels  
RIN5mF cells that were challenged with oxidants in the presence of 
conjugates were washed with Dulbecco's Phosphate Buffered Saline (DPBS) so 
that intracellular reactive oxygen species (ROS) could be detected. The cells 
were then incubated with 20 μM of the cell-permeant ROS indicator 2′, 7′-
dichlorodihydrofluorescein diacetate (H2DCF-DA, Invitrogen) prepared in 1mL 
PBS for 60 min at 37 °C. The nonfluorescent diacetate form (H2DCF-DA) is a 
nonpolar molecule that diffuses into RIN5mF cells and then undergoes hydrolysis 
by cellular esterases to become dichlorofluorescein (DCFH), a hydrophilic 
nonfluorescent compound that becomes trapped inside the cell. DCFH is further 
oxidized to a fluorescent derivate dichlorofluorescein (DCF) by intracellular free 
radicals. DCF fluorescence was measured in a plate reader with an 
excitation/emission wavelength of 485/530 nm (20). 
 
4.3.9 MTT assay for viability 
After incubating RIN5mF cells with oxidants and formulations for 24h, cell 
viability was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reduction assay (21). MTT was added to the wells 
at a final concentration of 0.5mg/ml and incubated at 37 °C under normal oxygen 
conditions for 3h. The medium was removed, and formazan crystals were 
solubilized by adding 1mL of dimethylsulfoxide (DMSO) and incubating the plates 
for 10min at 37 °C. Absorbance was measured at 570 nm using a microplate 
reader absorbance (SpectraMax\M2, Molecular devices; Sunnyvale, CA). The 
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data shown for the MTT assay are percentage cell viabilities expressed as 
means ± S.D. accumulated from three independent experiments.  
 
4.3.10 Insulin secretion assay  
Islets (50) that had been incubated with oxidants and conjugated 
hemoglobin in either hypoxia or normoxia and culture media were removed after 
24h, carefully rinsed with PBS, and placed in Kreb’s Ringers HEPES (KRH) 
solution containing Ca+2 and 15.6g/dL glucose (450G) and 0.5%w/v BSA (KRH = 
4.74mM KCl, 1.19mM KH2PO4, 1.19mM MgCl2.6H2O, 2.54mM CaCl2, 25 mM 
NaHCO3, 10 mM HEPES) (22). After 60min the medium was collected and 
insulin content was analyzed by RIA technique as per manufacturer instruction 
(125I-Insulin radioimmunoassay from MP Biomedicals, Inc). Insulin secretion was 
normalized to control islets incubated in medium only, and the percentage of 
insulin secretion is expressed as means ± S.D. n = 3.  
 
4.3.11  Confocal microscopy 
Isolated pancreatic beta-islets were placed in four-well LabTek chambers 
(VWR, Bridgeport, NJ) and were incubated with Hb conjugates and challenged 
with oxidants and then visually analyzed for cell viability using confocal 
microscopy. Combination of acridine orange (AO - stains live cells) and 
propidium iodide (PI - stains apoptotic cells) (100 μl AO/PI solution; 0.67 μg/ml 
AO and 75 μg/ml PI in PBS) dyes were islet permeabilized in the dark for 10min 
at room temperature prior to imaging (23). By exciting at 500 nm and 536 nm and 
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detecting emission at 530 nm and 620 nm for AO and PI, respectively, confocal 
images were obtained using the Fluoview confocal microscope (FV300, Olympus 
IX 81 microscope). Image J software (http://rsbweb.nih.gov/ij/) was used to 
analyze the images.  
 
4.3.12 Statistical analysis 
The statistical significance between the different experimental groups 
(control, oxidant, oxidant and Hb-Hb, oxidant and Hb-SOD-CAT) in different 
partial oxygen pressures was analyzed by analysis of variance to compare group 
means followed by Holm–Sidak test. P < 0.05 was considered to be statistically 
significant. All data are presented as means ± standard deviation. 
 
4.4. Results  
4.4.1 Visible absorbance changes and methemoglobin  
Overall results indicate that following a 24h challenge with hydrogen 
peroxide or superoxide anion at 37 °C, there was substantial protection of 
hemoglobin observed in conjugates cross-linked with antioxidant enzymes (Hb-
SOD-CAT) compared to Hb-only (Hb-Hb) conjugates (Figures 4.1 and 4.2). 
When Hb-Hb and Hb-SOD-CAT were compared for protective effect following the 
hydrogen peroxide or superoxide anion challenge, the decrease in characteristic 
hemoglobin absorbance read at 540 nm and 575 nm was higher for Hb-Hb than 
for Hb-SOD-CAT. The characteristic methemoglobin peak absorbance 
differences at 630 nm were higher for Hb-Hb and lower for Hb-SOD-CAT  
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Figure 4.1: Absorbance spectra of hemoglobin conjugates incubated with 1mM 
H2O2 at 21%, 6% or 1% oxygen for 24h at 37 °C. 
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Hb-Hb + 1mM X and 10mU/mL XO (6% O2) 
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Hb-SOD-CAT + 1mM X and 10mU/mL XO (1% O2)
 
 
Figure 4.2: Absorbance spectra of hemoglobin conjugates incubated with 1mM 
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between control and challenged conjugates at different partial (21%, 6%, and 
1%) oxygen levels. 
After a 24h incubation at 37 °C with 1mM hydrogen peroxide, the 
percentage of methemoglobin found in Hb-Hb conjugates was 74 ± 2%, 71 ± 
1%, and 72 ± 2% at 21%, 6%, and 1% oxygen levels, respectively, and 48 ± 
3%, 52 ± 2%, and 50 ± 1% at 21%, 6%, and 1% oxygen levels for Hb-SOD-
CAT (Figure 4.3). In this experiment, it was found that there were very few 
differences caused by different oxygen partial pressures, indicating that the 
oxygen content seems to have had a minimal effect in methemoglobin 
formation. In conjugates challenged with superoxide anion, the percentage 
methemoglobin formed in Hb-Hb was 62 ± 4%, 69 ± 3%, and 67 ± 1%; and for 
Hb-SOD-CAT conjugates the values were 44 ± 4%, 56 ± 2%, and 47 ± 1%, 
respectively, at 21%, 6%, and 1% oxygen levels (Figure 4.4). Statistical 
analysis showed significant differences in methemoglobin formation between 
Hb-Hb and Hb-SOD-CAT conjugates (p < 0.01) in 21%, 6%, and 1% oxygen. 
However, there was no statistical significance between the control conjugate 
samples and either peroxide or superoxide anion-challenged conjugates and 
incubated at the different oxygen partial pressures (p > 0.5). However, the 
results show an overall 20% lower methemoglobin formation when antioxidant 
enzymes were present in the cross-linked conjugate than the conjugates that 
did not contain antioxidant enzymes, at all different oxygen levels, and the 
results shows the usefulness of antioxidants. 
 




















Figure 4.3: Methemoglobin content in hemoglobin conjugates incubated with 
1mM H2O2 at 21%, 6% or 1% oxygen for 24h at 37 °C. 
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Figure 4.4: Methemoglobin content in hemoglobin conjugates incubated with 
1mM xanthine and 10mU/mL xanthine oxidase at 21%, 6% or 1% oxygen for 24h 
at 37 °C. 
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4.4.2 Intracellular free radical activity 
Intracellular free radical activity also can be measured to evaluate the 
capability of cells to adapt to external stressors or stimuli. When RINm5F cells 
were challenged with 1mM hydrogen peroxide and incubated with 0.1mM Hb-Hb, 
the relative fluorescence increased 16 ± 1%, 18 ± 1%, and 42 ± 6%; but when 
cells were incubated with 0.1mM Hb-SOD-CAT, the relative fluorescence 
increased only 3 ± 0.5%, 8 ± 1%, and 9 ± 1% (Figure 4.5). When the cells were 
incubated with 0.1mM Hb-Hb and challenged with superoxide anion, the relative 
fluorescence increased to14 ± 1%, 10 ± 1%, and 30 ± 3%; and when cells were 
incubated with 0.1mM Hb-SOD-CAT, the relative fluorescence increased only 3 ± 
0.5%, 3 ± 0.5%, and 5 ± 1%; in oxygen tensions 21%, 6%, and 1%, respectively, 
compared to an untreated control incubated in media only (Figure 4.6). Statistical 
significant differences existed, when RINm5F cells were treated with peroxide, 
between cells incubated with media only (no conjugates; p < 0.01) and Hb-Hb (p 
< 0.01) or Hb-SOD-CAT (p < 0.01). For superoxide anion challenge, significant 
differences existed between cells incubated with media only (no conjugates; p < 
0.01) and Hb-Hb (p < 0.01) or Hb-SOD-CAT at only 1% oxygen (p < 0.01). In 
addition, significant differences existed between Hb- Hb and Hb-SOD-CAT (p < 
0.01), for both peroxide and superoxide anion, in terms of the increase in 
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Figure 4.5: Intracellular free radical activity in RINm5F cells incubated with 
hemoglobin conjugates and challenged with 1mM H2O2 at 21%, 6% or 1% 
oxygen for 24h at 37 °C 
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Figure 4.6: Intracellular free radical activity in RINm5F cells incubated with 
hemoglobin conjugates and challenged with 1mM xanthine and 10mU/mL 
xanthine oxidase at 21%, 6% or 1% oxygen for 24h at 37 °C. 
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4.4.3 Viability of RINm5F cells 
The viability of RINm5F cells decreased from 100% (cells incubated in 
21%) to 30 ± 10%, 18 ± 14%, and 20 ± 11% when challenged with 1mM 
hydrogen peroxide and incubated for 24 hours at 37 °C at the different oxygen 
levels (21%, 6%, and 1%, respectively). Cells incubated with 1mM hydrogen 
peroxide and 0.1mM Hb-Hb without antioxidant enzymes at the different oxygen 
levels of 21%,6% and 1% had comparatively higher cell viabilities of 72 ± 15%, 
73 ± 9%, and 59 ± 8%, respectively (Figure 4.7). However, cells incubated with 
0.1mM Hb-SOD-CAT (with antioxidant enzymes) had cell viabilities of 96 ± 6%, 
87 ± 10%, and 88 ±15% for oxygen pressures of 21%, 6%, and 1%, and are 
comparable substantially to control cells in media incubated in 21% oxygen and 
higher than Hb-conjugates without antioxidant enzymes. Statistical analysis 
showed that there are no significant differences (p > 0.1) in cell protection 
between control cells in 21% oxygen and cells challenged by 1mM hydrogen 
peroxide and incubated with antioxidant enzymes (Hb-SOD-CAT) at all tested 
partial pressures (21%, 6%, and 1%) of oxygen. Statistical significance is 
observed between control cells in 21% oxygen to cells treated with 1mM 
hydrogen peroxide (p < 0.001), and 1mM hydrogen peroxide treated and 0.1mM 
incubated Hb-Hb without antioxidant enzymes (p < 0.05) at partial pressures 
(21%, 6%, and 1%) of oxygen, indicating the inability of Hb-Hb to protect cells in 
combined free radical and hypoxic stress. 
When RINm5F cells were incubated with superoxide anion generated by 
1mM xanthine and 10mU/mL xanthine oxidase, cell viability decreased to 33 ±  
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Figure 4.7: Relative cell viability of RINm5F cells incubated with hemoglobin 
conjugates and 1mM H2O2 at 21%, 6% or 1%) oxygen for 24h at 37 °C. 
 
11%, 35 ± 17%, and 31 ± 9% for 21%, 6%, and 1% oxygen, respectively 
(Figure 4.8). Cells incubated with superoxide anion and 0.1mM Hb-Hb had cell 
viabilities of 73 ± 8%, 72 ± 18%, and 56 ± 21% for 21%, 6%, and 1% oxygen, 
respectively. When cells were challenged with superoxide anion and incubated 
with 0.1mM Hb-SOD-CAT (containing antioxidant enzymes), RINm5F cells 
maintained viabilities of 93 ± 12%, 86 ± 11%, and 87 ± 7% at oxygen content of 
21% and 6% or 1% oxygen. Statistical analysis showed that there are no 
significant differences (p > 0.1) between control cells in 21% oxygen and cells 
challenged by superoxide anion and incubated with Hb-SOD-CAT at partial 
pressures (21%, 6%, and 1%) of oxygen, suggesting that antioxidant enzymes 
were successful in removing superoxide anion. Statistical significance is  
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Figure 4.8: Relative cell viability of RINm5F cells incubated with hemoglobin 
conjugates and 1mM xanthine and 10mU/mL xanthine oxidase at 21%, 6% or 1% 
oxygen for 24h at 37 °C. 
 
observed in cell killing when compared between control cells in 21% oxygen 
and cells treated with superoxide anion (p < 0.001) at partial pressures (21%, 
6%, and 1%) of oxygen. In addition, superoxide anion-treated cells incubated 
with Hb-Hb without antioxidant enzymes (p < 0.05) also showed differences at 
1% oxygen, indicating the inability of Hb-Hb alone to protect cells in severe 
combined free-radical and 1% hypoxic stress. 
 
4.4.4 Insulin release by pancreatic beta islets  
Insulin release from pancreatic islets challenged with 1mM hydrogen 
peroxide or superoxide anion and incubated in 21%, 6%, and 1% oxygen for 24h 
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followed by a 25mM glucose challenge test showed significant retention of the 
insulin release function for islets incubated with hemoglobin conjugates 
containing antioxidant enzyme (Hb-SOD-CAT), when normalized to control islets 
(21% oxygen) and compared to islets incubated with hemoglobin conjugates 
without antioxidant enzymes (Hb-Hb). 
In 21% oxygen, islets only (no conjugates) challenged with 1mM hydrogen 
peroxide showed reduced insulin release of 21 ± 31%, islets incubated with Hb-
Hb showed insulin release of 29 ± 26%, and islets incubated with Hb-SOD-CAT 
released 84 ± 29% insulin compared to control healthy islets (Figure 4.9). When 
exposed to 1mM hydrogen peroxide at 6% partial oxygen pressure, insulin 
release was 32 ± 13% for islets (no conjugates) and 33 ± 35% for islets and Hb-
Hb, but was maintained at 86 ± 21% for islets with Hb-SOD-CAT when 
normalized to control islets cultured at 21% oxygen. For 1mM hydrogen peroxide 
exposure at 1% partial oxygen partial pressure, insulin secretion was 31 ± 10% 
for islets (no conjugates), 39 ± 10% for islets with Hb-Hb, and 86 ± 29% for islets 
incubated with Hb-SOD-CAT, when normalized to control islets cultured at 21% 
oxygen. Statistical significance was observed between control islets (no 
conjugates, 21% oxygen) and 1mM hydrogen peroxide-incubated islets (p < 
0.005) and peroxide with Hb-Hb incubated islets (p < 0.01), suggesting 
substantial loss of insulin-secreting capability of islets at all partial pressures 
(21%, 6%, and 1%) of oxygen. In addition, the insulin-secretion differences were 
insignificant (p > 0.4) with Hb-SOD-CAT-incubated islets and show the direct 
and/or indirect protection of islets by antioxidant enzymes. 
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Hb-Hb + 1mM H202 
Hb-SOD-CAT + 1mM H202  
 
 
Figure 4.9: Relative insulin secretion from isolated rat pancreatic islets incubated 
with hemoglobin conjugates and 1mM H2O2 at 21%, 6% or 1% oxygen for 24h at 
37 °C. 
 
Superoxide anion-challenged islets (1mM xanthine and 10mU/mL 
xanthine oxidase) had reduced insulin secretion to 44 ± 22%, 23 ± 7%, and 21 ± 
26% with superoxide anion only; and with superoxide anion and Hb-Hb 
incubation, reduced insulin release to 41 ± 36%, 30 ± 5%, and 22 ± 33%. Insulin 
release was maintained at 83 ± 22%, 77 ± 31%, and 94 ± 20% with superoxide 
anion and Hb-SOD-CAT incubation at 21%, 6%, and 1% partial oxygen 
pressures, respectively, and 37 °C for 24h challenge (Figure 4.10). Insulin 
secretion levels were statistically insignificant (p > 0.2) between islets (no 
conjugates, 21% oxygen) and islets challenged with superoxide anion and  
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1mM X +10 mU/mL XO 
Hb-Hb + 1mM X +10 mU/mL XO 
Hb-SOD-CAT + 1mM X +10 mU/mL XO 
 
Figure 4.10: Relative insulin secretion from isolated rat pancreatic islets 
incubated with hemoglobin conjugates and 1mM xanthine and 10mU/mL 
xanthine oxidase at 21%, 6% or 1% oxygen for 24h at 37 °C. 
 
incubated with Hb-SOD-CAT, showing the protection from free radical and 
hypoxic damage at tested partial oxygen pressures (21%, 6%, and 1%). The 
insulin secretions were statistically significant for islets challenged with 
superoxide anion (p < 0.01), and superoxide and Hb-Hb incubated islets (p < 
0.01) at partial pressures (21%, 6%, and 1%) of oxygen. 
 
4.4.5 Qualitative confocal microscopic image analysis 
of pancreatic beta cells  
Control pancreatic islets incubated in 21% oxygen show high uptake of 
AO and no uptake of PI, indicating complete cell viability (Figure 4.11). Islets  
 
 




Figure 4.11: Confocal images of isolated rat pancreatic islets incubated with 
hemoglobin conjugates and either 1mM H2O2 or 1mM xanthine (X) and 10mU/mL 
xanthine oxidase (XO) at 21% oxygen for 24h at 37 °C. 
(A) Control  1% O2 (B) 1mM H2O2 (C) 1mM H2O2 + Hb-Hb (D) 1mM H2O2 + Hb-
SOD-CAT (E) 1mM X and 10mU/mL XO (F) 1mM X and 10mU/mL XO + Hb-Hb 
(G) 1mM X and 10mU/mL XO +Hb-SOD-CAT (original magnification × 100). 
 
incubated in 6% or 1% oxygen showed higher uptake of AO with little uptake of 
PI, indicating the susceptibility of islets to hypoxic stress (Figure 4.12 and 4.13). 
Islets only (no conjugates) and islets incubated with 0.1mM Hb-Hb and 
challenged with 1mM hydrogen peroxide had shown high uptake of PI with 
minimal uptake of AO at partial oxygen pressures (21%, 6% or 1% oxygen) 
indicating islet damage. Islets that were incubated with 0.1mM Hb-SOD-CAT 
and challenged with 1mM hydrogen peroxide showed high uptake of AO and 
minimal uptake of PI, indicating that there was significant islet protection from 
combined stress conferred by the hemoglobin and antioxidant enzymes in Hb-
SOD-CAT in tested partial oxygen pressures. 
 
 




Figure 4.12: Confocal images of isolated rat pancreatic islets incubated with 
hemoglobin conjugates and either 1mM H2O2 or 1mM xanthine (X) and 10mU/mL 
xanthine oxidase (XO) at 6% oxygen for 24h at 37 °C. 
(A) Control  1% O2 (B) 1mM H2O2 (C) 1mM H2O2 + Hb-Hb (D) 1mM H2O2 + Hb-
SOD-CAT (E) 1mM X and 10mU/mL XO (F) 1mM X and 10mU/mL XO + Hb-Hb 






Figure 4.13: Confocal images of isolated rat pancreatic islets incubated with 
hemoglobin conjugates and either 1mM H2O2 or 1mM xanthine (X) and 10mU/mL 
xanthine oxidase (XO) at 21%, %6 or 1% oxygen for 24h at 37 °C. 
(A) Control  1% O2 (B) 1mM H2O2 (C) 1mM H2O2 + Hb-Hb (D) 1mM H2O2 + Hb-
SOD-CAT (E) 1mM X and 10mU/mL XO (F) 1mM X and 10mU/mL XO + Hb-Hb 
(G) 1mM X and 10mU/mL XO +Hb-SOD-CAT (original magnification × 100). 
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 Islets only (no conjugates) that were challenged with superoxide anion 
(1mM xanthine and 10mU/mL of xanthine oxidase) showed increased uptake of 
PI and minimal or decreased uptake of AO, indicating there was cell damage 
caused by the superoxide anion. Islets incubated with 0.1mM Hb-Hb and 
exposed to superoxide anion also showed uptake of PI and had qualitative 
images similar to superoxide-challenged islets only (no conjugates). However, 
when islets were incubated with Hb-SOD-CAT and exposed to superoxide anion, 
PI uptake was minimal and AO uptake was high, indicating that islets were well-
protected from the combined stresses of superoxide anion damage and hypoxia 
over 24h in 21%, 6%, and 1% oxygen.  
 
4.5 Discussion 
Many factors hamper beta-cell function before and after islet 
transplantation (24-27). Hypoxic and oxidative stress plays an important role, and 
research reports suggest the need for protection of beta-cells by oxygenating 
(28) and using antioxidant enzymes (9). Even before transplantation, islets are 
subjected to metabolic adaptation because of isolation (29). Hemoglobin, the 
oxygen carrier, is the most important component of the conjugate system that 
needs protection from free-radical stress if it is going to extend the oxygen 
release and protect isolated beta-cells during hypoxic stress. Visible absorbance 
spectrum results on PEG-conjugated hemoglobins (Hb:PEG 1:10 molar ratio) 
had shown a substantial decrease of available hemoglobin and showed 
increased absorbance peak values at 630 nm, which represents the increased 
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non-oxygen-carrying methemoglobin formation in Hb-Hb cross-linked conjugates 
than conjugates with antioxidant enzymes (Hb-SOD-CAT). The results 
demonstrate with both the oxidants (superoxide anion and peroxide) that free 
radical damaging effects on hemoglobin are more rapid and prominent for the 
oxidant concentrations used in the experiment than the differences caused by 
oxygen partial pressures (21, 6%, and 1%) at 37 °C and within 24h. 
Methemoglobin levels were higher in Hb-Hb conjugates without the antioxidant 
enzymes SOD and CAT, thus the damage caused by hydrogen peroxide and 
superoxide anion on hemoglobin. Although methemoglobin is formed in Hb-SOD-
CAT oxidant-incubated conjugates, results show that the levels are 
approximately much lower when antioxidant enzymes are present and 
emphasize the need for their addition to inhibit the conversion of hemoglobin to 
methemoglobin. If necessary, this amount of methemoglobin may be further 
decreased by increasing the amount of antioxidant enzymes in the cross-linked 
conjugates.  
It was reported that H2O2 concentration in normal human plasma ranges 
between 4-5 µM and increased in the inflammatory conditions (30, 31). In in vivo 
transplantation sites, the oxidant conditions on hemoglobin may not be as harsh 
as the in vitro experiments. Studies from another ascorbate-glutathione system 
also strongly suggested the need for an antioxidant system to inhibit the pro-
oxidant effect of acellular hemoglobins (12). Previously, it was also reported that 
higher methemoglobin levels are formed in hemoglobin systems as the partial 
oxygen levels are decreased (32). On the contrary, the effect of different oxygen 
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levels (21%, 6%, and 1%) in the tested incubator seems to play an insignificant 
role when compared to the amount of the hydrogen peroxide or superoxide anion 
levels for 24h and at 37 °C incubation. However, in these studies, the effect may 
also be confounded by the oxidants’ effects, or the effect by partial oxygen 
pressures may become more prominent in in vivo experiments longer than 24h. 
These observed results clearly show the rationale for inclusion of antioxidant 
enzymes in the conjugates for protection of hemoglobin from both hypoxia-
induced and exogenous free radical stresses. 
The cell viability of RINm5F cells challenged with oxidants measured the 
active mitochondrial MTT conversion to formazan (purple-shaped crystals). 
Results in RINm5F cells had demonstrated that cross-linked Hb-SOD-CAT 
offered higher cell protection in terms of percentage of relative cell viability than 
an Hb-Hb conjugate without the antioxidant enzymes from both combined 
oxygen tension (21%, 6%, and 1% oxygen) and peroxide or superoxide anion 
free radical stress. Higher cell viability observed in RINm5F cells incubated with 
Hb-SOD-CAT may be attributed primarily to the better protection of hemoglobin 
from free radical stress and thus the extended protection of cells from both 
hypoxia and free radical damages. Protection of RINm5F cells even with Hb-Hb 
conjugates incubated with oxidants may be oxidants had attacked hemoglobin 
initially than RINm5F cells.  The cells are spared from hypoxic and free radical 
stress initially and as hemoglobin is degraded, hypoxia and further reactive active 
species might have acted and resulted on RINm5F cell death at latter stages. 
However, complete cell death in extended incubations beyond 24h studies can 
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be expected with Hb-Hb conjugates without antioxidant enzymes. Reduced 
intracellular ROS production with HB-SOD-CAT when compared to Hb-Hb 
seemed to be efficient in protecting the cells from the harmful effect of the 
oxidants. These results complement the viability results in RINm5F cells.  
When cells are subjected to external stresses, cell death is the end point, 
and many metabolic functions may be shut down long before the cell death as a 
defense mechanism to protect cells from eventual cell death (33). Functions such 
as insulin release are affected highly in beta cells in hypoxic and free radical 
conditions (34-36). The results show that Hb-SOD-CAT had either protected or 
enhanced the insulin release by beta cells at tested partial oxygen pressures 
when challenged with free radical generating peroxide or superoxide anion in 
hypoxic conditions when normalized to the control islets in 21% oxygen. The 
results show the beneficial effect in restoring the metabolic function of islets from 
either combined peroxide challenge or superoxide anion challenge in hypoxia 
and retention or enhancement of insulin release function by the hemoglobin 
conjugated with antioxidant enzyme (Hb-SOD-CAT).  
The combination of the fluorescent dyes AO (binds to DNA in viable cells) 
and PI (only permeable into apoptotic cells) also helped to qualitatively 
distinguish the cell death and viability of beta-cells. Isolated pancreatic beta-cells 
incubated with hydrogen peroxide and superoxide anion and by Hb-Hb 
conjugates without antioxidant enzymes in different partial oxygen pressures did 
not completely protect islets from free radical and hypoxic damage and thus 
emphasize the need for the addition of antioxidant enzymes into Hb-Hb cross-
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linking. Hb-SOD-CAT conjugate incubated beta cells had shown minimal uptake 
of PI and the primary reason may be attributed to effective higher oxygen supply 
from the conjugated hemoglobins in severe hypoxic environments and free 
radical stress when antioxidant enzymes are used for the direct protection of Hb 
damage and beta- cells. These results strongly suggest that Hb-SOD-CAT may 
be an appropriate strategy to prevent hypoxia-induced graft failure in conditions 
such as encapsulated islet transplantation and ischemia re-perfusion injury (37). 
The hemoglobin function in a hypoxic environment is more effective in supplying 
oxygen when antioxidant enzymes protect Hb damage from free radical 
environment and thus shows the requirement for (Hb-SOD-CAT) design. 
 
4.6. Conclusion 
In this work, it is demonstrated the effectiveness of the Hb-SOD-CAT 
conjugate system for overall function of beta-cells similar to transplantation 
conditions. Cells incubated with only Hb-Hb in hypoxic conditions and free radical 
environment without antioxidant enzymes showed increased cell death in 
combined hypoxic and free radical environment. The hemoglobin function in a 
hypoxic environment is more effective in supplying oxygen when antioxidant 
enzymes protect Hb damage. These results strongly demonstrate the beneficial 
effect of adding SOD and CAT for the protection of hemoglobin and/or beta-cells 
against hypoxic and oxidative stresses and thus the inhibition of methemoglobin 
formation to extend oxygen supply.  
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5.1  General conclusions 
The biohybrid artificial pancreas approach employing encapsulated islets 
with biocompatible polymers offers an immunoprotective environment that could 
overcome some limitations of the current antidiabetic therapy. Numerous 
research studies reported that the separation of islets renders them susceptible 
to hypoxic and free-radical stress, causing enhanced apoptosis at the site of 
transplantation. Newer technologies such as stem cells may provide the solutions 
for the islet scarcity. The critical problems associated with hypoxia, which 
reduces insulin secretion, need to be addressed to successfully advance the islet 
transplantation and to achieve clinical success. The research project focused on 
solving the primary problem of hypoxia-associated death in islets by using low 
p50 hemoglobin (Hb) and of free-radical stress (hypoxia associated) by using the 
antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT). The 
ultimate goal of the work is to enhance the cell viability of beta-cells to potentially 
provide a long-term continuous secretion of insulin after transplantation for 
advancement toward a biohybrid artificial pancreas.  
The first part of the study focused on cross-linking Hb with SOD and CAT 
enzymes to stabilize the proteins and increase the molecular size of conjugates 
intended for the retention in the microcapsules to prevent diffusional loss. A 
suitable polymer was chosen to reduce the conversion of hemoglobin to 
methemoglobin during cross-linking. For the long-term protection of Hb from 
oxidative stress during storage or at the transplantation site, either by auto-




cross-linked along with Hb. Retention of enzymatic activity was also confirmed 
after cross-linking the enzymes SOD and CAT with HB. The results proved that 
Hb can be significantly protected by using the current method of PEG cross-
linking. The conversion of hemoglobin to methmoglobin by oxidative stress was 
also verified and found to be minimal by the cross-linking approach. The above 
results helped to predict that Hb may extend oxygen delivery function in 
scenarios that involve free-radical stress. Different cross-linking ratios of PEG/Hb 
were screened, and the ratio 1:10 was found to be optimal for further studies. 
Overall, the use of antioxidant enzymes in cross-linking introduced a new type of 
PEG-modified hemoglobin oxygen carrier. 
The second part focused on whether low p50 characteristics of Hb helps 
in simulated situations of hypoxia-induced stress. The protective effect evaluated 
on pancreatic beta cells (RINm5F) from hypoxia (6%, 3%, and 1% oxygen) by an 
MTT assay and confocal microscopy showed Hb conjugates with antioxidant 
enzymes offered significant protection (p < 0.01, increased viability ~ 80%) from 
hypoxia compared to control cells in 1% oxygen. The higher protection of 
RINm5F cells with Hb conjugates when compared to free Hb may be primarily 
because of the differences in their p50 characteristics. This work provided a 
polymer-based cross-linking approach to lower the p50 of hemoglobin for 
optimization of O2 carriers, intended for therapeutic or prophylactic benefits from 
hypoxia and ischemic conditions. This study also demonstrated a general design 
approach for protecting isolated cells or tissues from combined hypoxia-induced 




usefulness of Hb-SOD-CAT for the overall function of beta-cells when exposed to 
conditions mimicking islet transplantation. 
Hemoglobin is the most important component of the conjugate systems 
and needs first-hand protection from free radical stress for it to extend the 
protection function on cells by oxygen release. Visible absorption spectrum 
results showed a substantial decrease in non-oxygen-carrying methemoglobin 
formation with antioxidant enzymes (Hb-SOD-CAT) and thus the protection of 
hemoglobin in a harsh free radical environment. The results demonstrated that 
free-radical damage by both superoxide anion and hydrogen peroxide is more 
rapid and prominent on Hb than the differences in oxygen partial pressures.  
The cell viability results on RINm5F cells demonstrated that cross-linked 
Hb-SOD-CAT offered better cell protection in terms of relative cell viability from 
both combined oxygen tension and peroxide or superoxide anion free-radical 
stress. Confocal microscopy helped to qualitatively distinguish the protection on 
pancreatic beta islets in the combined hypoxic and oxidative conditions, and the 
results showed that Hb-SOD-CAT offered better cell protection. Insulin release 
by beta cells at all partial oxygen pressures was retained when beta cells were 
subjected to combined oxidative and hypoxic stresses and tested by glucose-
induced insulin secretion. Reduced intracellular ROS production with HB-SOD-
CAT also has demonstrated the effectiveness of conjugate systems in protecting 
the cells from oxidants.  
These results show the potential of Hb-SOD-CAT in preventing the beta-




encountered during transplantation or for clinical situations such as organ 
preservation for transplantation. 
 
5.2 Future work 
5.2.1 Optimization of co-encapsulated cross-linked Hb-SOD-CAT  
and islets within microcapsules 
This work will demonstrate whether islets and Hb-SOD-CAT can 
effectively be co-encapsulated into the microcapsules and the system can be 
functional with the islet   post encapsulation. Ideally, a single islet in one 
microcapsule may function better. Depending upon whether a single islet or 
multiple islets are encapsulated, the amount of Hb-SOD-CAT in a single 
microcapsule needs to be optimized. Low amounts of Hb-SOD-CAT may not 
provide enough oxygen content to the islet. The compatibility between the 
capsule-forming material and Hb-SOD-CAT should also be tested. Incompatible 
capsule-forming materials may cause imperfections in the capsule morphologies, 
such as tapering ends of the capsules, which will create pores and thus not retain 
Hb-SOD-CAT and/or islets. These imperfections may also create entry into the 
capsule by other molecules or cells that may have damaging or immune-
generating activity on islets and eventually may lead to partially encapsulated 
islet death. The entire capsule system (capsule material, islet, and Hb-SOD-CAT) 
should also be tested in vitro in hypoxia and/or hypoxia-induced free radical 




help in further selection and optimization of microcapsules for efficient islet 
delivery and thus the prolonged insulin secretion at transplantation site. 
 
5.2.2 Transplantation studies in diabetic animal models 
Optimized microcapsules should be further tested in the Type 1 diabetic 
models. Type 1 diabetic animal models are widely used for studying the 
effectiveness of the antidiabetic drug therapy. The first is the chemically induced 
diabetic rat model, in which diabetes is induced by streptozotocin (STZ). The 
second is the spontaneous autoimmune type with nonobese diabetic (NOD) 
mice, in which diabetes is induced by viral infection. Even though these two 
models differ only in the way of generating a experimental diabetic model, the 
results will help researchers understand how efficiently the proposed approach 
works in the preclinical stage. 
Microencapsulated islets with co-encapsulated Hb-SOD-CAT should be 
transplanted at different common islet transplantation sites (peritoneal, portal, 
etc.) by measuring the partial oxygen pressures. The effectiveness of the whole 
approach should be tested by frequently collecting blood samples and measuring 
blood glucose levels. The in vivo glucose level estimation will help in 
understanding the ability of the encapsulated islets and the number islets needed 
to achieve normoglycemia in the diabetic preclinical model. The effectiveness 
and protection of islets at the transplantation sites can be further tested by 
retrieving microcapsules and challenging with glucose for the islet ability to 




(quality) before and after transplantation and thus the robustness of islet 
protection in the capsule. Hemoglobin and islets quality should also be assessed 
in decapsulating conditions. The protection of the hemoglobin at the actual 
transplantation site will also help the usefulness of antioxidant enzymes in 
protecting the hemoglobin from free radical and auto-oxidation. 
 
